AXA/2025/FY/Earnings presentation: Difference between revisions
Appearance
< AXA
Content deleted Content added
PlumBot: publish from draft |
PlumBot: publish from draft |
||
| Line 18: | Line 18: | ||
=== Full Year 2025 earnings presentation === |
=== Full Year 2025 earnings presentation === |
||
* ''' |
* '''AXA Full Year 2025''' earnings presentation delivered on February 26, 2026 <sup>p. 1</sup> |
||
* '''Presentation date''': February 26, 2026 <sup>p. 1</sup> |
|||
=== Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures === |
=== Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures === |
||
* ''' |
* '''Forward-looking statements''' include predictions, trends, plans, expectations, or objectives based on Management's current views and subject to change <sup>p. 2</sup>. |
||
* '''Expected UEPS growth''' for 2026 is provided as one-off guidance in the context of the |
* '''Expected UEPS growth''' for 2026 is provided as one-off guidance in the context of the final year of the Group's current strategic plan <sup>p. 2</sup>. |
||
* '''Risk factors''' are described in Part 5 "Risk Factors and Risk Management" of AXA's Universal Registration Document |
* '''Risk factors''' and uncertainties that may affect AXA's business are described in Part 5 "Risk Factors and Risk Management" of AXA's 2024 Universal Registration Document <sup>p. 2</sup>. |
||
* ''' |
* '''Alternative performance measures''' (APMs) used include "underlying earnings", UEPS ("underlying earnings per share"), "underlying return on equity", "combined ratio", and "debt gearing" <sup>p. 2</sup>. |
||
** APMs are defined under ESMA guidelines and the AMF's 2015 position statement, with reconciliations provided in AXA's 2025 Activity Report <sup>p. 2</sup>. |
|||
* '''Financial statements''' for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure <sup>p. 2</sup>. |
|||
* '''Financial statements status''': AXA's consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of audit procedures <sup>p. 2</sup>. |
|||
=== Table of contents === |
=== Table of contents === |
||
| Line 37: | Line 37: | ||
== FY25 Highlights == |
== FY25 Highlights == |
||
* |
* Section divider slide for '''FY25 Highlights''', presented by Thomas Buberl, Group CEO <sup>p. 4</sup>. |
||
=== Full Year 2025 | Excellent performance === |
=== Full Year 2025 | Excellent performance === |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable fintable" |
||
|+ Key financial highlights, FY25 <sup>p. 5</sup> |
|+ Key financial highlights, FY25 <sup>p. 5</sup> |
||
! style="text-align:left" | Metric |
! style="text-align:left" | Metric |
||
! class="col- |
! class="col-m" style="text-align:right" | Value |
||
|- |
|- |
||
| style="text-align:left" | Revenues |
| style="text-align:left" | Revenues growth vs. FY24 |
||
| |
| style="text-align:right" | +6% |
||
|- |
|- |
||
| style="text-align:left" | Underlying EPS |
| style="text-align:left" | Underlying EPS growth vs. FY24 |
||
| |
| style="text-align:right" | +8% |
||
|- |
|- |
||
| style="text-align:left" | Return on equity |
| style="text-align:left" | Return on equity |
||
| |
| style="text-align:right" | 16% |
||
|- |
|- |
||
| style="text-align:left" | Solvency II ratio |
| style="text-align:left" | Solvency II ratio |
||
| |
| style="text-align:right" | 224% |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | DPS growth |
||
| |
| style="text-align:right" | +8% |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Annual share buyback |
||
| |
| style="text-align:right" | EUR 1.25bn |
||
|- |
|- |
||
| style="text-align:left" | Underlying EPS |
| style="text-align:left" | Underlying EPS outlook for 2026 |
||
| |
| style="text-align:right" | Upper end of 6%-8% target range |
||
|} |
|} |
||
</div> |
</div> |
||
* |
* Dividend proposal based on Board of Directors' recommendation on February 25, 2026, subject to Shareholders' Annual General Meeting approval on April 30, 2026 |
||
* Share buyback approved by the Board of Directors on February 25, 2026, expected to commence as soon as reasonably practicable, subject to market conditions |
|||
=== Executing the plan on growth, margin and efficiency === |
=== Executing the plan on growth, margin and efficiency === |
||
| Line 79: | Line 80: | ||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change (constant FX) |
||
! class="col-s" style="text-align:right" | Change excluding AXA IM |
! class="col-s" style="text-align:right" | Change (excluding AXA IM) |
||
|- |
|- |
||
| style="text-align:left" | Underlying earnings |
| style="text-align:left" | Underlying earnings |
||
| Line 89: | Line 90: | ||
|} |
|} |
||
</div> |
</div> |
||
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) |
|||
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency |
|||
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) <sup>p. 6</sup> |
|||
* Scaling the business: Continued investments in growth and technology |
|||
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency <sup>p. 6</sup> |
|||
* Consistent earnings growth while enhancing reserve prudence |
|||
* Scaling the business: Continued investments in growth and technology <sup>p. 6</sup> |
|||
* Consistent earnings growth while enhancing reserve prudence <sup>p. 6</sup> |
|||
=== Diversified franchise, well positioned in an attractive industry === |
=== Diversified franchise, well positioned in an attractive industry === |
||
| Line 99: | Line 99: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Gross written premium split (FY25, excluding AXA IM and holdings) <sup>p. 7</sup> |
||
! style="text-align:left" | Segment |
! style="text-align:left" | Segment |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share |
||
| Line 111: | Line 111: | ||
| style="text-align:left" | Large & Specialty |
| style="text-align:left" | Large & Specialty |
||
| style="text-align:right" | 17% |
| style="text-align:right" | 17% |
||
|- |
|||
| style="text-align:left" | SME & Mid-market |
|||
| style="text-align:right" | 16% |
|||
|- |
|- |
||
| style="text-align:left" | Retail |
| style="text-align:left" | Retail |
||
| style="text-align:right" | 17% |
| style="text-align:right" | 17% |
||
|- |
|||
| style="text-align:left" | SME & Mid-market |
|||
| style="text-align:right" | 16% |
|||
|} |
|} |
||
</div> |
</div> |
||
* Secular trends |
* '''Secular trends''' fuel demand across businesses, driven by protection gaps and emerging corporate risks, as well as demographics driving demand for private retirement and healthcare |
||
* Our right to win is supported by four |
* '''Our right to win''' is supported by four strategic pillars: |
||
** Leading brand & high customer NPS |
** Leading brand & high customer NPS |
||
** Strong and diversified distribution |
** Strong and diversified distribution |
||
** Technical expertise to price & underwrite risks |
** Technical expertise to price & underwrite risks |
||
** Scale offering cost advantage |
** Scale offering cost advantage |
||
=== Laying the foundation for the next plan === |
=== Laying the foundation for the next plan === |
||
* '''Strategic pillars''' established to lay the foundation for the next plan |
* '''Strategic pillars''' established to lay the foundation for the next plan: |
||
** Clear tech and AI roadmap <sup>p. 8</sup> |
** '''Clear tech''' and AI roadmap <sup>p. 8</sup> |
||
** Driving efficiency <sup>p. 8</sup> |
** '''Driving efficiency''' across operations <sup>p. 8</sup> |
||
** Enhancing capital allocation discipline <sup>p. 8</sup> |
** '''Enhancing capital''' allocation discipline <sup>p. 8</sup> |
||
** Building resilience <sup>p. 8</sup> |
** '''Building resilience''' across the business <sup>p. 8</sup> |
||
* '''Earnings growth |
* '''Earnings growth''' outlook supported by strong foundations, providing confidence in sustaining earnings growth <sup>p. 8</sup> |
||
== Business Performance == |
== Business Performance == |
||
| Line 150: | Line 150: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable" |
||
|+ |
|+ Gross written premiums and underlying earnings by region FY25 <sup>p. 10</sup> |
||
! style="text-align:left" | Region |
! style="text-align:left" | Region (share of total GWP¹) |
||
! class="col-m" style="text-align:right" | Gross written premiums |
! class="col-m" style="text-align:right" | Gross written premiums |
||
! class="col-m" style="text-align:right" | Underlying earnings |
! class="col-m" style="text-align:right" | Underlying earnings |
||
|- |
|- |
||
| style="text-align:left" | France (27% of total GWP¹) |
| style="text-align:left" | '''France''' (27% of total GWP¹) |
||
| class="col-m" style="text-align:right" | +6% to EUR 31bn |
| class="col-m" style="text-align:right" | +6% to EUR 31bn |
||
| class="col-m" style="text-align:right" | +7% to EUR 2.2bn |
| class="col-m" style="text-align:right" | +7% to EUR 2.2bn |
||
|- |
|- |
||
| style="text-align:left" | Europe (38% of total GWP¹) |
| style="text-align:left" | '''Europe''' (38% of total GWP¹) |
||
| class="col-m" style="text-align:right" | +6% to EUR 43bn |
| class="col-m" style="text-align:right" | +6% to EUR 43bn |
||
| class="col-m" style="text-align:right" | +9% to EUR 3.5bn |
| class="col-m" style="text-align:right" | +9% to EUR 3.5bn |
||
|- |
|- |
||
| style="text-align:left" | AXA XL (17% of total GWP¹) |
| style="text-align:left" | '''AXA XL''' (17% of total GWP¹) |
||
| class="col-m" style="text-align:right" | +4% to EUR 19bn |
| class="col-m" style="text-align:right" | +4% to EUR 19bn |
||
| class="col-m" style="text-align:right" | +9% to EUR 1.9bn |
| class="col-m" style="text-align:right" | +9% to EUR 1.9bn |
||
|- |
|- |
||
| style="text-align:left" | Asia, Africa & EME-LATAM (18% of total GWP¹) |
| style="text-align:left" | '''Asia, Africa & EME-LATAM''' (18% of total GWP¹) |
||
| class="col-m" style="text-align:right" | +13% to EUR 20bn |
| class="col-m" style="text-align:right" | +13% to EUR 20bn |
||
| class="col-m" style="text-align:right" | +6% to EUR 1.5bn |
| class="col-m" style="text-align:right" | +6% to EUR 1.5bn |
||
| Line 175: | Line 175: | ||
=== P&C | Strong margins, confidence in sustaining growth === |
=== P&C | Strong margins, confidence in sustaining growth === |
||
* '''Gross written premiums''' (GWP) |
* '''Gross written premiums''' (GWP) reached EUR 58bn <sup>p. 11</sup>. |
||
* (donut) '''GWP mix''': Retail, AXA XL (Large & Specialty), SME & Mid-market — shares not labeled <sup>p. 11</sup>. |
* (donut) '''GWP mix''': Retail, AXA XL (Large & Specialty), SME & Mid-market — shares not labeled <sup>p. 11</sup>. |
||
** AXA XL GWP includes AXA XL Re premiums of EUR 2.6bn <sup>p. 11</sup>. |
|||
* '''Underlying earnings''' +9% at constant FX to EUR 5.9bn <sup>p. 11</sup>. |
* '''Underlying earnings''' +9% at constant FX to EUR 5.9bn <sup>p. 11</sup>. |
||
* '''Retail and SME & Mid-market |
* '''Retail and SME & Mid-market''' strategic outlook: |
||
** '''2025''': Growing volumes while expanding margins <sup>p. 11</sup>. |
** '''2025''': Growing volumes while expanding margins <sup>p. 11</sup>. |
||
** '''Beyond 2025''': Investing to improve customer retention and expanding distribution footprint <sup>p. 11</sup>. |
** '''Beyond 2025''': Investing to improve customer retention and expanding distribution footprint <sup>p. 11</sup>. |
||
* '''AXA XL (Large & Specialty) |
* '''AXA XL (Large & Specialty)''' strategic outlook: |
||
** '''2025''': Profitable growth with stable margins <sup>p. 11</sup>. |
** '''2025''': Profitable growth with stable margins <sup>p. 11</sup>. |
||
** '''Beyond 2025''': Capitalizing on attractive growth opportunities and continued cycle management <sup>p. 11</sup>. |
** '''Beyond 2025''': Capitalizing on attractive growth opportunities and continued cycle management <sup>p. 11</sup>. |
||
* '''Earnings drivers''': |
* '''Earnings drivers''' supporting performance: |
||
** Continued progress on efficiency <sup>p. 11</sup>. |
** Continued progress on efficiency <sup>p. 11</sup>. |
||
** Higher investment income <sup>p. 11</sup>. |
** Higher investment income <sup>p. 11</sup>. |
||
| Line 191: | Line 192: | ||
=== L&H | Good momentum, well positioned to capture growth opportunities === |
=== L&H | Good momentum, well positioned to capture growth opportunities === |
||
* '''Gross written premiums''' (GWP) reached EUR 57bn <sup>p. 12</sup>. |
|||
<div style="overflow-x:auto"> |
|||
* (donut) '''GWP mix''': Short-term and Long-term segments — shares not labeled <sup>p. 12</sup>. |
|||
{| class="wikitable fintable" |
|||
* '''Underlying earnings''' +7% LFL to EUR 3.5bn (change FY25 vs. FY24 at constant FX) <sup>p. 12</sup>. |
|||
|+ Financial highlights and strategic priorities <sup>p. 12</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | Value |
|||
|- |
|||
| style="text-align:left" | Gross written premiums (GWP) |
|||
| style="text-align:right" | 57 |
|||
|- |
|||
| style="text-align:left" | Underlying earnings |
|||
| style="text-align:right" | 3.5 |
|||
|} |
|||
</div> |
|||
* (donut) '''GWP mix''': Short-term and Long-term segments — shares not labeled. |
|||
* '''Long-term business''' strategic priorities: |
* '''Long-term business''' strategic priorities: |
||
** '''2025''': Accelerating net flows in Savings at attractive margins. |
** '''2025''': Accelerating net flows in Savings at attractive margins <sup>p. 12</sup>. |
||
** '''Beyond 2025''': Capturing savings & retirement opportunity, sourcing best asset management products for our customers. |
** '''Beyond 2025''': Capturing savings & retirement opportunity, sourcing best asset management products for our customers <sup>p. 12</sup>. |
||
* '''Short-term business''' strategic priorities: |
* '''Short-term business''' strategic priorities: |
||
** '''2025''': Growing technical results while absorbing Mexico VAT impact. |
** '''2025''': Growing technical results while absorbing Mexico VAT impact <sup>p. 12</sup>. |
||
** '''Beyond 2025''': Capitalizing on demand for health & protection while further improving our margins. |
** '''Beyond 2025''': Capitalizing on demand for health & protection while further improving our margins <sup>p. 12</sup>. |
||
* ''' |
* '''Strategic levers''' for growth and efficiency: |
||
** Focus on cost reduction. |
** Focus on cost reduction <sup>p. 12</sup>. |
||
** Increasing penetration of Protection riders in Savings offerings. |
** Increasing penetration of Protection riders in Savings offerings <sup>p. 12</sup>. |
||
** Leveraging AI to reduce claims leakage & improve customer outcomes in Health. |
** Leveraging AI to reduce claims leakage & improve customer outcomes in Health <sup>p. 12</sup>. |
||
* '''Underlying earnings''' +7% at constant FX to EUR 3.5bn <sup>p. 12</sup>. |
|||
== Financial Performance == |
== Financial Performance == |
||
| Line 227: | Line 216: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ P&C GWP |
|+ P&C GWP & other revenues by segment, FY24 vs FY25 <sup>p. 14</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | o/w pricing |
! class="col-s" style="text-align:right" | o/w pricing |
||
! class="col-s" style="text-align:right" | o/w volume |
! class="col-s" style="text-align:right" | o/w volume |
||
| Line 264: | Line 253: | ||
|} |
|} |
||
</div> |
</div> |
||
* |
* Continued pricing momentum and volume growth in Mid-market and SME |
||
* |
* Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance |
||
* |
* Growth supported by alternative capital |
||
* |
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) |
||
=== P&C | Delivering further margin expansion while enhancing reserve prudence === |
=== P&C | Delivering further margin expansion while enhancing reserve prudence === |
||
| Line 273: | Line 262: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Combined ratio |
|+ Combined ratio bridge, FY24 vs FY25 <sup>p. 15</sup> |
||
! style="text-align:left" | Combined ratio |
! style="text-align:left" | Combined ratio |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 303: | Line 292: | ||
|} |
|} |
||
</div> |
</div> |
||
* |
* Undiscounted CY loss ratio (ex Nat Cat) improved from: |
||
** Margin expansion in |
** Margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment |
||
** Stable |
** Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management |
||
* |
* Expense ratio improved reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology |
||
* |
* Nat Cat charges below normalized load |
||
* |
* Prior year reserve development shows lower reliance |
||
* |
* Reserve prudence enhanced by taking advantage of a good year |
||
=== P&C | Earnings growth from higher underwriting and financial result === |
=== P&C | Earnings growth from higher underwriting and financial result === |
||
| Line 344: | Line 333: | ||
|} |
|} |
||
</div> |
</div> |
||
* Underlying earnings grew +9% at constant FX to EUR 5,872m |
* Underlying earnings grew +9% at constant FX to EUR 5,872m. |
||
* Underwriting result |
* Underwriting result improved from strong volume growth and improved all-year combined ratio while enhancing reserve prudence. |
||
* Investment income increased reflecting higher volumes and better reinvestment yields on fixed income assets. |
|||
* Financial result driven by investment income (+EUR 435m) and partly offset by insurance finance expenses (-EUR 235m) <sup>p. 16</sup>. |
|||
* Insurance finance expenses impacted by higher unwind of discount of claims reserves, in line with guidance. |
|||
* Underwriting result improved from strong volume growth and improved all-year combined ratio while enhancing reserve prudence <sup>p. 16</sup>. |
|||
* Forex impact was unfavorable, notably due to USD depreciation vs. EUR. |
|||
* Investment income increased reflecting higher volumes and better reinvestment yields on fixed income assets <sup>p. 16</sup>. |
|||
* Insurance finance expenses impacted by higher unwind of discount of claims reserves, in line with guidance <sup>p. 16</sup>. |
|||
* Forex impact was unfavorable notably due to USD depreciation vs. EUR <sup>p. 16</sup>. |
|||
=== Life & Health | Strong growth in premiums, positive net flows === |
=== Life & Health | Strong growth in premiums, positive net flows === |
||
| Line 356: | Line 343: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ GWP and other revenues by line, FY24 vs FY25 <sup>p. 17</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | LFL Change |
! class="col-s" style="text-align:right" | LFL Change |
||
|- |
|||
| style="text-align:left" | Life GWP |
|||
| style="text-align:right" | 34.5 |
|||
| style="text-align:right" | 37.5 |
|||
| style="text-align:right" | +9% |
|||
|- |
|- |
||
| style="text-align:left" | Protection |
| style="text-align:left" | Protection |
||
| Line 382: | Line 374: | ||
| style="text-align:right" | -7% |
| style="text-align:right" | -7% |
||
|- |
|- |
||
| style="text-align:left |
| style="text-align:left" | Health GWP |
||
| style="text-align:right |
| style="text-align:right" | 17.5 |
||
| style="text-align:right |
| style="text-align:right" | 19.0 |
||
| style="text-align:right |
| style="text-align:right" | +5% |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Health GWP & Other Revenues mix, FY24 vs FY25 <sup>p. 17</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | LFL Change |
|||
|- |
|- |
||
| style="text-align:left" | Individual |
| style="text-align:left" | Individual |
||
| Line 407: | Line 389: | ||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
|- |
|- |
||
| style="text-align:left |
| style="text-align:left" | Employee Benefits GWP |
||
| style="text-align:right |
| style="text-align:right" | — |
||
| style="text-align:right |
| style="text-align:right" | 12.9 |
||
| style="text-align:right |
| style="text-align:right" | +4% |
||
|} |
|} |
||
</div> |
</div> |
||
| Line 416: | Line 398: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Net flows by segment <sup>p. 17</sup> |
|+ Net flows by segment, FY24 vs FY25 <sup>p. 17</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | 1.5 |
|||
| style="text-align:right; font-weight:bold" | 5.4 |
|||
|- |
|- |
||
| style="text-align:left" | Protection |
| style="text-align:left" | Protection |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
| style="text-align:right" | 4.9 |
|||
|- |
|- |
||
| style="text-align:left" | Health |
| style="text-align:left" | Health |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
| style="text-align:right" | 2.7 |
|||
|- |
|- |
||
| style="text-align:left" | Unit-Linked |
| style="text-align:left" | Unit-Linked |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
| style="text-align:right" | 1.5 |
|||
|- |
|- |
||
| style="text-align:left" | Capital light G/A |
| style="text-align:left" | Capital light G/A |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
| style="text-align:right" | 1.2 |
|||
|- |
|- |
||
| style="text-align:left" | Traditional G/A |
| style="text-align:left" | Traditional G/A |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | -5.0 |
| style="text-align:right" | -5.0 |
||
|} |
|} |
||
</div> |
</div> |
||
* Employee Benefits GWP and other revenues (including both short-term and long-term) was EUR 12.9bn (+4% vs. FY24) <sup>p. 17</sup> |
|||
* Net flows reached +EUR 5.4bn (vs. +EUR 1.5bn in FY24) <sup>p. 17</sup> |
|||
=== Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
=== Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
||
| Line 443: | Line 433: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ PVEP trend, FY24 vs FY25 <sup>p. 18</sup> |
|+ PVEP trend by segment, FY24 vs FY25 <sup>p. 18</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | LFL Change |
! class="col-s" style="text-align:right" | LFL Change |
||
|- |
|||
| style="text-align:left; font-weight:bold" | Total PVEP |
|||
| style="text-align:right; font-weight:bold" | 50.9 |
|||
| style="text-align:right; font-weight:bold" | 49.4 |
|||
| style="text-align:right; font-weight:bold" | -2% |
|||
|- |
|- |
||
| style="text-align:left" | Protection & Health |
| style="text-align:left" | Protection & Health |
||
| Line 468: | Line 463: | ||
| style="text-align:right" | 1.7 |
| style="text-align:right" | 1.7 |
||
| style="text-align:right" | -10% |
| style="text-align:right" | -10% |
||
|- |
|||
| style="text-align:left; font-weight:bold" | Total PVEP |
|||
| style="text-align:right; font-weight:bold" | 50.9 |
|||
| style="text-align:right; font-weight:bold" | 49.4 |
|||
| style="text-align:right; font-weight:bold" | -2% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 478: | Line 468: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ NB CSM |
|+ NB CSM and NBV, FY24 vs FY25 <sup>p. 18</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | LFL Change |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | NB CSM (pre-tax) |
||
| style="text-align:right" | 2.2 |
|||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
| style="text-align:right" | +3% |
|||
|- |
|||
| style="text-align:left" | NBV (post-tax) |
|||
| style="text-align:right" | 2.3 |
| style="text-align:right" | 2.3 |
||
|- |
|||
| style="text-align:left" | FY25 |
|||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
| style="text-align:right" | 2.2 |
|||
|- |
|||
| style="text-align:left" | LFL Change |
|||
| style="text-align:right" | +3% |
|||
| style="text-align:right" | stable |
| style="text-align:right" | stable |
||
|} |
|} |
||
</div> |
</div> |
||
* '''PVEP''' impacted by higher interest rates on discounting despite strong growth in Life volumes <sup>p. 18</sup>. |
|||
<div style="overflow-x:auto"> |
|||
* '''NB CSM''' driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits <sup>p. 18</sup>. |
|||
{| class="wikitable fintable" |
|||
* '''NBV''' broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France <sup>p. 18</sup>. |
|||
|+ NBV margin, FY24 vs FY25 <sup>p. 18</sup> |
|||
* '''NBV margin''': 4.4% in FY24 → 4.5% in FY25 <sup>p. 18</sup> |
|||
! style="text-align:left" | — |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|||
| style="text-align:left" | NBV margin |
|||
| style="text-align:right" | 4.4% |
|||
| style="text-align:right" | 4.5% |
|||
|} |
|||
</div> |
|||
* PVEP impacted by higher interest rates on discounting despite strong growth in Life volumes <sup>p. 18</sup> |
|||
* NB CSM driven by robust Savings & Protection sales; reported growth impacted by higher interest rates for discounting of future profits <sup>p. 18</sup> |
|||
* NBV broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France <sup>p. 18</sup> |
|||
=== Life & Health | Growth in new business driving Normalized CSM growth === |
=== Life & Health | Growth in new business driving Normalized CSM growth === |
||
| Line 519: | Line 497: | ||
|+ Contractual Service Margin rollforward, FY24 to FY25 <sup>p. 19</sup> |
|+ Contractual Service Margin rollforward, FY24 to FY25 <sup>p. 19</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Value |
||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 |
||
| Line 547: | Line 525: | ||
</div> |
</div> |
||
* '''Normalized CSM''' up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates <sup>p. 19</sup> |
|||
<div style="overflow-x:auto"> |
|||
* '''Economic variance''' reflecting government spreads tightening and positive equity market returns <sup>p. 19</sup> |
|||
{| class="wikitable fintable" |
|||
* '''Operating variance''' driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland <sup>p. 19</sup> |
|||
|+ Contractual Service Margin by segment <sup>p. 19</sup> |
|||
* '''FX impact''' mainly from JPY and HKD depreciation <sup>p. 19</sup> |
|||
! style="text-align:left" | EUR billion |
|||
* (waterfall) '''Contractual Service Margin rollforward''' (in EUR billion): FY24 EUR 33.6bn (o/w Life EUR 25.8bn, o/w Health EUR 7.7bn) → New business CSM +EUR 2.2bn → Underlying return on in-force +EUR 1.3bn → CSM release -EUR 3.0bn (Normalized CSM growth +2%) → Economic variance +EUR 0.6bn → Operating variance -EUR 0.3bn → Affiliates, FX & other -EUR 1.4bn → FY25 EUR 33.0bn (o/w Life EUR 25.4bn, o/w Health EUR 7.6bn) <sup>p. 19</sup> |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|||
| style="text-align:left" | Life segment |
|||
| style="text-align:right" | 25.8 |
|||
| style="text-align:right" | 25.4 |
|||
|- |
|||
| style="text-align:left" | Health segment |
|||
| style="text-align:right" | 7.7 |
|||
| style="text-align:right" | 7.6 |
|||
|} |
|||
</div> |
|||
* '''Normalized CSM''' up by +2% LFL, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates <sup>p. 19</sup>. |
|||
* '''Economic variance''' reflecting government spreads tightening and positive equity market returns <sup>p. 19</sup>. |
|||
* '''Operating variance''' driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland <sup>p. 19</sup>. |
|||
* '''FX impact''' mainly from JPY and HKD depreciation <sup>p. 19</sup>. |
|||
* '''Normalized CSM growth''' +2% (comprising New business CSM, Underlying return on in-force, and CSM release) <sup>p. 19</sup> |
|||
=== Life & Health | Strong momentum in both short-term and long-term business === |
=== Life & Health | Strong momentum in both short-term and long-term business === |
||
| Line 575: | Line 536: | ||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying earnings bridge, FY24 to FY25 <sup>p. 20</sup> |
|+ Underlying earnings bridge, FY24 to FY25 <sup>p. 20</sup> |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Underlying earnings |
! class="col-s" style="text-align:right" | Underlying earnings |
||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 start |
||
| style="text-align:right" | 3,323 |
| style="text-align:right" | 3,323 |
||
|- |
|- |
||
| Line 593: | Line 554: | ||
| style="text-align:right" | -27 |
| style="text-align:right" | -27 |
||
|- |
|- |
||
| style="text-align:left" | FY25 |
| style="text-align:left" | FY25 end |
||
| style="text-align:right" | 3,501 |
| style="text-align:right" | 3,501 |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Underlying earnings components <sup>p. 20</sup> |
|||
! style="text-align:left" | EUR million |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|||
| style="text-align:left" | Short-term technical margin |
|||
| style="text-align:right" | 415 |
|||
| style="text-align:right" | 479 |
|||
|- |
|||
| style="text-align:left" | Long-term result incl. CSM release |
|||
| style="text-align:right" | 2,680 |
|||
| style="text-align:right" | 2,804 |
|||
|- |
|||
| style="text-align:left" | Financial result |
|||
| style="text-align:right" | 975 |
|||
| style="text-align:right" | 946 |
|||
|- |
|||
| style="text-align:left" | Tax & others |
|||
| style="text-align:right" | -748 |
|||
| style="text-align:right" | -728 |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Underlying earnings by segment <sup>p. 20</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|||
| style="text-align:left" | Life |
|||
| style="text-align:right" | 2.6 |
|||
| style="text-align:right" | 2.7 |
|||
| style="text-align:right" | +4% |
|||
|- |
|||
| style="text-align:left" | Health |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | 0.8 |
|||
| style="text-align:right" | +17% |
|||
|} |
|} |
||
</div> |
</div> |
||
* '''Underlying earnings''' +7% LFL to EUR 3,501m <sup>p. 20</sup> |
* '''Underlying earnings''' +7% LFL to EUR 3,501m <sup>p. 20</sup> |
||
* |
* '''Short-term technical margin''': EUR 415m in FY24 to EUR 479m in FY25 <sup>p. 20</sup> |
||
* |
* '''Long-term result''' incl. CSM release: EUR 2,680m in FY24 to EUR 2,804m in FY25 <sup>p. 20</sup> |
||
* '''Financial result''': EUR 975m in FY24 to EUR 946m in FY25 <sup>p. 20</sup> |
|||
* '''Tax & others''': EUR -748m in FY24 to EUR -728m in FY25 <sup>p. 20</sup> |
|||
* '''Life underlying earnings''' +4% to EUR 2.7bn (prior: EUR 2.6bn) <sup>p. 20</sup> |
|||
* '''Health underlying earnings''' +17% to EUR 0.8bn (prior: EUR 0.7bn) <sup>p. 20</sup> |
|||
* '''Short-term margin''' strong on underwriting and claims initiatives; more than offset legislative change on Mexico VAT recoverability of EUR -0.1bn <sup>p. 20</sup> |
|||
* '''Long-term results''' higher from CSM release increase of +8% on reserve base growth, favorable equity markets, and better margins <sup>p. 20</sup> |
|||
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM === |
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM === |
||
| Line 651: | Line 573: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Earnings and net income breakdown |
|+ Earnings and net income breakdown FY24 vs FY25 <sup>p. 21</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 677: | Line 599: | ||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
|- |
|- |
||
| style="text-align:left" | Underlying earnings |
| style="text-align:left" | '''Underlying earnings''' |
||
| style="text-align:right" | 8.1 |
| style="text-align:right" | 8.1 |
||
| style="text-align:right" | 8.4 |
| style="text-align:right" | 8.4 |
||
| Line 697: | Line 619: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Net income |
| style="text-align:left" | '''Net income''' |
||
| style="text-align:right" | 7.9 |
| style="text-align:right" | 7.9 |
||
| style="text-align:right" | 9.8 |
| style="text-align:right" | 9.8 |
||
| Line 706: | Line 628: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying earnings per share |
|+ Underlying earnings per share bridge, FY24 to FY25 <sup>p. 21</sup> |
||
! style="text-align:left" | EUR |
! style="text-align:left" | EUR |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Underlying earnings per share |
||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 3.59 |
| style="text-align:right" | 3.59 |
||
| style="text-align:right" | 3.86 |
|||
| style="text-align:right" | +8% |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Underlying earnings per share change drivers <sup>p. 21</sup> |
|||
! style="text-align:left" | Driver |
|||
! class="col-s" style="text-align:right" | Contribution |
|||
|- |
|- |
||
| style="text-align:left" | Earnings growth |
| style="text-align:left" | Earnings growth |
||
| Line 734: | Line 644: | ||
| style="text-align:right" | -2% |
| style="text-align:right" | -2% |
||
|- |
|- |
||
| style="text-align:left" | AXA IM sale |
| style="text-align:left" | Temporary earnings dilution from AXA IM sale |
||
| style="text-align:right" | -1% |
| style="text-align:right" | -1% |
||
|- |
|||
| style="text-align:left" | FY25 |
|||
| style="text-align:right" | 3.86 |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 745: | Line 658: | ||
** Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM <sup>p. 21</sup> |
** Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM <sup>p. 21</sup> |
||
** Lower financial flows reflecting unfavorable forex impact <sup>p. 21</sup> |
** Lower financial flows reflecting unfavorable forex impact <sup>p. 21</sup> |
||
* Change is at constant FX for underlying earnings and net income; change is on a reported basis for underlying earnings per share <sup>p. 21</sup> |
|||
* (bar) '''Underlying earnings per share''' (In Euro): EUR 3.59 in FY24 to EUR 3.86 in FY25 (+8%) <sup>p. 21</sup> |
|||
=== Shareholders' equity === |
=== Shareholders' equity === |
||
* (stacked bar) '''Shareholders' equity''' Group share: |
|||
<div style="overflow-x:auto"> |
|||
** '''FY24''': EUR 49.9bn total (comprising SHE excl. OCI EUR 58.0bn and Net OCI EUR -8.1bn) <sup>p. 22</sup> |
|||
{| class="wikitable fintable" |
|||
** '''HY25''': EUR 45.5bn total (comprising SHE excl. OCI EUR 52.7bn and Net OCI EUR -7.2bn) <sup>p. 22</sup> |
|||
** '''FY25''': EUR 47.2bn total (comprising SHE excl. OCI EUR 54.0bn and Net OCI EUR -6.8bn) <sup>p. 22</sup> |
|||
! style="text-align:left" | EUR billion unless otherwise mentioned |
|||
* '''SHE (excl. OCI & undated subordinated debt)''': EUR 53.2bn in FY24 → EUR 47.0bn in HY25 → EUR 49.4bn in FY25 <sup>p. 22</sup> |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
* '''Debt gearing''': 20.6% in FY24 → 23.4% in HY25 → 22.3% in FY25 <sup>p. 22</sup> |
|||
! class="col-s" style="text-align:right" | HY25 |
|||
* '''Underlying ROE''': 15.2% in FY24 → 17.5% in HY25 → 16.0% in FY25 <sup>p. 22</sup> |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|||
| style="text-align:left" | Shareholders' equity (Group share) total |
|||
| style="text-align:right" | 49.9 |
|||
| style="text-align:right" | 45.5 |
|||
| style="text-align:right" | 47.2 |
|||
|- |
|||
| style="text-align:left" | SHE (excl. OCI) |
|||
| style="text-align:right" | 58.0 |
|||
| style="text-align:right" | 52.7 |
|||
| style="text-align:right" | 54.0 |
|||
|- |
|||
| style="text-align:left" | Net OCI |
|||
| style="text-align:right" | -8.1 |
|||
| style="text-align:right" | -7.2 |
|||
| style="text-align:right" | -6.8 |
|||
|- |
|||
| style="text-align:left" | SHE (excl. OCI & undated subordinated debt) |
|||
| style="text-align:right" | 53.2 |
|||
| style="text-align:right" | 47.0 |
|||
| style="text-align:right" | 49.4 |
|||
|- |
|||
| style="text-align:left" | Debt gearing |
|||
| style="text-align:right" | 20.6% |
|||
| style="text-align:right" | 23.4% |
|||
| style="text-align:right" | 22.3% |
|||
|- |
|||
| style="text-align:left" | Underlying ROE |
|||
| style="text-align:right" | 15.2% |
|||
| style="text-align:right" | 17.5% |
|||
| style="text-align:right" | 16.0% |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Shareholders' equity roll-forward |
|+ Shareholders' equity roll-forward <sup>p. 22</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 to FY25 |
! class="col-s" style="text-align:right" | FY24 to FY25 |
||
! class="col-s" style="text-align:right" | HY25 to FY25 |
! class="col-s" style="text-align:right" | HY25 to FY25 |
||
| Line 836: | Line 719: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''Reporting currency''' is in Euro billion <sup>p. 22</sup>. |
|||
=== Higher organic cash remittance and robust cash position at Holding === |
=== Higher organic cash remittance and robust cash position at Holding === |
||
* '''Net cash remittance''' |
* (bar) '''Net cash remittance''' trend: |
||
** |
** '''FY24''': EUR 7.7bn total, comprising EUR 7.1bn ordinary remittance and EUR 0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe <sup>p. 23</sup> |
||
** ''' |
** '''FY25''': EUR 7.5bn total <sup>p. 23</sup> |
||
* '''Remittance ratio''' remained stable at 82% in FY24 and 82% in FY25, based on ordinary cash remittance of EUR 7.1bn in FY24 and EUR 7.5bn in FY25 <sup>p. 23</sup> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Holding cash position bridge FY24 to FY25 |
|+ Holding cash position bridge FY24 to FY25 in Euro billion <sup>p. 23</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | — |
||
|- |
|||
| style="text-align:left" | '''FY24 Cash position''' |
|||
| style="text-align:right" | 4.0 |
|||
|- |
|- |
||
| style="text-align:left" | Net cash remittance from subsidiaries |
| style="text-align:left" | Net cash remittance from subsidiaries |
||
| Line 871: | Line 757: | ||
| style="text-align:right" | +3.1 |
| style="text-align:right" | +3.1 |
||
|- |
|- |
||
| style="text-align:left" | FY25 Cash position |
| style="text-align:left" | '''FY25 Cash position''' |
||
| style="text-align:right" | 5.6 |
| style="text-align:right" | 5.6 |
||
|} |
|} |
||
| Line 928: | Line 814: | ||
</div> |
</div> |
||
* Foreseeable dividends accounted for -EUR 4.8bn. |
|||
* Dividend & annual share buyback includes foreseeable dividends of -EUR 4.8bn and provision for annual share buyback for 2026 of -EUR 1.25bn <sup>p. 24</sup>. |
|||
* Provision for annual share buyback for 2026 accounted for -EUR 1.25bn. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Key sensitivities of Solvency II ratio as of December 31, 2025 <sup>p. 24</sup> |
|+ Key sensitivities of Solvency II ratio as of December 31, 2025 (base 224%) <sup>p. 24</sup> |
||
! style="text-align:left" | Sensitivity |
! style="text-align:left" | Sensitivity |
||
! class="col-s" style="text-align:right" | Impact (pts) |
! class="col-s" style="text-align:right" | Impact (pts) |
||
| Line 951: | Line 838: | ||
| style="text-align:right" | -4 |
| style="text-align:right" | -4 |
||
|- |
|- |
||
| style="text-align:left" | Listed Equity ( |
| style="text-align:left" | Listed Equity (excluding PE & Infra) +25% |
||
| style="text-align:right" | -1 |
| style="text-align:right" | -1 |
||
|- |
|- |
||
| style="text-align:left" | Listed Equity ( |
| style="text-align:left" | Listed Equity (excluding PE & Infra) -25% |
||
| style="text-align:right" | +2 |
| style="text-align:right" | +2 |
||
|- |
|- |
||
| Line 968: | Line 855: | ||
</div> |
</div> |
||
* Euro sovereign spreads sensitivity assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve, applied on sovereign and quasi-sovereign exposures. |
|||
* Solvency II ratio increased to 224% in FY25 from 216% in FY24 <sup>p. 24</sup>. |
|||
* |
* Credit rating migration sensitivity assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches). |
||
* Credit rating migration sensitivity assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches) <sup>p. 24</sup>. |
|||
=== Solvency II -impact of the end of grandfathering period and Solvency II revision === |
=== Solvency II -impact of the end of grandfathering period and Solvency II revision === |
||
| Line 977: | Line 863: | ||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Solvency II ratio impacts <sup>p. 25</sup> |
|+ Solvency II ratio impacts <sup>p. 25</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Event |
||
! class="col- |
! class="col-s" style="text-align:right" | Impact (pts) |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Solvency II ratio as of December 31, 2025 |
||
| style="text-align:right" | 224 |
| style="text-align:right" | 224 |
||
|- |
|- |
||
| style="text-align:left" | Grandfathering end impact on January 1, 2026 |
| style="text-align:left" | Grandfathering end impact on January 1, 2026 |
||
| style="text-align:right" | - |
| style="text-align:right" | -10 |
||
|- |
|- |
||
| style="text-align:left" | Solvency II revision impact to come into effect in 1Q27 |
| style="text-align:left" | Solvency II revision impact to come into effect in 1Q27 |
||
| style="text-align:right" | + |
| style="text-align:right" | +17 |
||
|} |
|} |
||
</div> |
</div> |
||
* EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026 |
* EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026. |
||
* No change is expected in organic capital generation. |
|||
* Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date <sup>p. 25</sup>. |
|||
* Provides additional capital flexibility. |
|||
* No change is expected in organic capital generation <sup>p. 25</sup>. |
|||
* Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date. |
|||
* Provides additional capital flexibility <sup>p. 25</sup>. |
|||
* '''Grandfathering end impact''' on January 1, 2026 is -10pts to 215% <sup>p. 25</sup>. |
|||
=== Thomas Buberl, Group CEO conclusion === |
=== Thomas Buberl, Group CEO conclusion === |
||
* ''' |
* '''Section divider''' for the conclusion presentation by Thomas Buberl, Group CEO <sup>p. 26</sup>. |
||
=== Conclusion === |
=== Conclusion === |
||
* '''Record results''' achieved at the top end of the target range while enhancing reserve prudence <sup>p. 27</sup>. |
* '''Record results''' achieved at the top end of the target range while enhancing reserve prudence <sup>p. 27</sup>. |
||
* ''' |
* '''All businesses''' in excellent shape, delivering strong growth and profitability <sup>p. 27</sup>. |
||
* '''Diversified franchise''' |
* '''Diversified franchise''' well-positioned to capture future growth opportunities <sup>p. 27</sup>. |
||
* ''' |
* '''Laying foundations''' for the next plan and confident in delivering sustainable earnings growth <sup>p. 27</sup>. |
||
=== February 26, 2026 Q&A Full Year 2025 earnings === |
=== February 26, 2026 Q&A Full Year 2025 earnings === |
||
* ''' |
* '''Q&A session''' for the Full Year 2025 Earnings presentation held on February 26, 2026 <sup>p. 28</sup>. |
||
* '''Date''': February 26, 2026 <sup>p. 28</sup> |
|||
=== AXA Investor Relations | Keep in touch === |
=== AXA Investor Relations | Keep in touch === |
||
| Line 1,019: | Line 905: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable" |
||
|+ Meet our management event |
|+ Meet our management event schedule <sup>p. 29</sup> |
||
! style="text-align:left" | Date |
! style="text-align:left" | Date |
||
! class="col-m" style="text-align:right" | Event |
! class="col-m" style="text-align:right" | Event |
||
| Line 1,052: | Line 938: | ||
== Appendices == |
== Appendices == |
||
* Section divider |
* Section divider for '''Appendices''' <sup>p. 30</sup> |
||
=== Table of contents === |
=== Table of contents === |
||
| Line 1,063: | Line 949: | ||
=== Gross financial debt and maturity breakdown as of December 31st, 2025 === |
=== Gross financial debt and maturity breakdown as of December 31st, 2025 === |
||
<div style="overflow-x:auto"> |
|||
* (stacked bar) '''Gross financial debt''': |
|||
{| class="wikitable fintable" |
|||
** '''FY24''': EUR 19.2bn total; Tier 1 EUR 4.8bn, Tier 2 EUR 10.8bn, Senior debt EUR 3.5bn; debt gearing at 20.6% <sup>p. 32</sup> |
|||
|+ Gross financial debt <sup>p. 32</sup> |
|||
** '''FY25''': EUR 20.3bn total; Tier 1 EUR 4.6bn, Tier 2 EUR 12.2bn, Senior debt EUR 3.5bn; debt gearing at 22.3% <sup>p. 32</sup> |
|||
! style="text-align:left" | EUR billion unless otherwise mentioned |
|||
** '''Jan 1st 2026''' (End of the grandfathering period): EUR 20.3bn total; Tier 1 EUR 3.2bn, Tier 2 EUR 11.3bn, Senior debt EUR 5.8bn (of which EUR 0.4bn redeemed in Jan 2026) <sup>p. 32</sup> |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
* (stacked bar) '''Contractual maturity breakdown''': |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
** '''2028''': Senior debt EUR 0.5bn <sup>p. 32</sup> |
|||
! class="col-s" style="text-align:right" | Jan 1st 2026 |
|||
** '''2030''': Tier 2 EUR 0.7bn, Senior debt EUR 0.9bn <sup>p. 32</sup> |
|||
|- |
|||
** '''2031-2039''': Senior debt EUR 1.5bn <sup>p. 32</sup> |
|||
| style="text-align:left" | Tier 1 |
|||
** '''≥2040''': Tier 2 EUR 10.8bn, Senior debt EUR 0.5bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 4.8 |
|||
** '''Undated''': Tier 1 EUR 4.6bn, Tier 2 EUR 0.7bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 4.6 |
|||
** '''Of which grandfathered debt''': Tier 1 Undated EUR 1.4bn; Tier 2 2030 EUR 0.7bn, ≥2040 EUR 0.2bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 3.2 |
|||
* (stacked bar) '''Economic maturity breakdown''': |
|||
|- |
|||
** '''2026''': Tier 1 EUR 0.1bn <sup>p. 32</sup> |
|||
| style="text-align:left" | Tier 2 |
|||
** '''2027''': Tier 2 EUR 2.4bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 10.8 |
|||
** '''2028''': Tier 1 EUR 0.1bn, Senior debt EUR 0.5bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 12.2 |
|||
** '''2029''': Tier 2 EUR 2.0bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 11.3 |
|||
** '''2030''': Tier 2 EUR 0.7bn, Senior debt EUR 0.9bn <sup>p. 32</sup> |
|||
|- |
|||
** '''2031-2039''': Tier 1 EUR 0.4bn, Tier 2 EUR 6.4bn, Senior debt EUR 1.5bn <sup>p. 32</sup> |
|||
| style="text-align:left" | Senior debt |
|||
| style="text-align:right" | 3.5 |
|||
** '''Undated''': Tier 1 EUR 4.0bn, Tier 2 EUR 0.7bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 3.5 |
|||
** '''Of which grandfathered debt''': Tier 1 2026 EUR 0.1bn, 2028 EUR 0.1bn, 2031-2039 EUR 0.4bn, Undated EUR 0.8bn; Tier 2 2030 EUR 0.7bn, ≥2040 EUR 0.2bn <sup>p. 32</sup> |
|||
| style="text-align:right" | 5.8 |
|||
* '''Debt redemptions''' called in January 2026: remaining T2 GF GBP 139m due 2054 callable 2034 5.625% issued January 2014, and T1 GF EUR 250m perpetual callable 2010 floating issued January 2005 <sup>p. 32</sup> |
|||
|- |
|||
* '''Economic maturity''' accounts for the first date of step-up calls on institutionally placed subordinated debt; Solvency II RT1 debt with no step-up retains its undated nature <sup>p. 32</sup> |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | 19.2 |
|||
| style="text-align:right; font-weight:bold" | 20.3 |
|||
| style="text-align:right; font-weight:bold" | 20.3 |
|||
|- |
|||
| style="text-align:left" | Debt gearing |
|||
| style="text-align:right" | 20.6% |
|||
| style="text-align:right" | 22.3% |
|||
| style="text-align:right" | — |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Contractual maturity breakdown <sup>p. 32</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | Tier 1 |
|||
! class="col-s" style="text-align:right" | Tier 2 |
|||
! class="col-s" style="text-align:right" | Senior debt |
|||
|- |
|||
| style="text-align:left" | 2028 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.5 |
|||
|- |
|||
| style="text-align:left" | 2030 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | 0.9 |
|||
|- |
|||
| style="text-align:left" | 2031-2039 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 1.5 |
|||
|- |
|||
| style="text-align:left" | ≥2040 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 10.8 |
|||
| style="text-align:right" | 0.5 |
|||
|- |
|||
| style="text-align:left" | Undated |
|||
| style="text-align:right" | 4.6 |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Grandfathered debt (contractual) |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 1 Undated |
|||
| style="text-align:right" | 1.4 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 2 2030 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 2 ≥2040 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.2 |
|||
| style="text-align:right" | — |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Economic maturity breakdown <sup>p. 32</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | Tier 1 |
|||
! class="col-s" style="text-align:right" | Tier 2 |
|||
! class="col-s" style="text-align:right" | Senior debt |
|||
|- |
|||
| style="text-align:left" | 2026 |
|||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | 2027 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 2.4 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | 2028 |
|||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.5 |
|||
|- |
|||
| style="text-align:left" | 2029 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 2.0 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | 2030 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | 0.9 |
|||
|- |
|||
| style="text-align:left" | 2031-2039 |
|||
| style="text-align:right" | 0.4 |
|||
| style="text-align:right" | 6.4 |
|||
| style="text-align:right" | 1.5 |
|||
|- |
|||
| style="text-align:left" | ≥2040 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.5 |
|||
|- |
|||
| style="text-align:left" | Undated |
|||
| style="text-align:right" | 4.0 |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Grandfathered debt (economic) |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 1 2026 |
|||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 1 2028 |
|||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 1 2031-2039 |
|||
| style="text-align:right" | 0.4 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 1 Undated |
|||
| style="text-align:right" | 0.8 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 2 2030 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tier 2 ≥2040 |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | 0.2 |
|||
| style="text-align:right" | — |
|||
|} |
|||
</div> |
|||
* In January 2026, AXA called the remaining Tier 2 grandfathered GBP 139m due 2054 callable 2034 (5.625% issued January 2014) and the Tier 1 grandfathered EUR 250m perpetual callable 2010 floating (issued January 2005). |
|||
* Economic maturity accounts for the first date of step-up calls on institutionally placed subordinated debt. |
|||
* For Solvency II RT1 debt with no step-up, the undated nature of the instrument is retained for economic maturity. |
|||
=== General account invested assets === |
=== General account invested assets === |
||
* '''Total General Account''' invested assets |
* '''Total General Account''' invested assets at EUR 450bn <sup>p. 33</sup>. |
||
* '''Duration gap''' |
* '''Duration gap''' at -0.4 year <sup>p. 33</sup>. |
||
* (donut) '''FY25 |
* (donut) '''FY25 General Account invested assets''': EUR 450bn total; mix includes Fixed income, Real estate, Infrastructure equity, Listed equities, Private equity and hedge funds, Cash, and Policy loans <sup>p. 33</sup>. |
||
* '''Other fixed income''' includes Asset Backed Securities (EUR 25bn), Residential Loans (EUR 16bn), Commercial & Agricultural Loans (EUR 7bn), and Agency Pools (EUR 8bn) <sup>p. 33</sup>. |
|||
* '''Listed equities''' includes hedges; listed equities excluding hedges at EUR 14bn <sup>p. 33</sup>. |
|||
* '''Private equity and hedge funds''' includes Private Equity (EUR 17bn), Hedge Funds (EUR 5bn), and Non-listed Equities (EUR 1bn) <sup>p. 33</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Invested assets |
|+ Invested assets breakdown FY25 <sup>p. 33</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | % |
! class="col-s" style="text-align:right" | % |
||
| Line 1,112: | Line 1,156: | ||
| style="text-align:right" | 27% |
| style="text-align:right" | 27% |
||
|- |
|- |
||
| style="text-align:left" | ''o/w Other fixed income |
| style="text-align:left" | ''o/w Other fixed income'' |
||
| style="text-align:right" | 56 |
| style="text-align:right" | 56 |
||
| style="text-align:right" | 13% |
| style="text-align:right" | 13% |
||
| Line 1,124: | Line 1,168: | ||
| style="text-align:right" | 2% |
| style="text-align:right" | 2% |
||
|- |
|- |
||
| style="text-align:left" | '''Listed equities |
| style="text-align:left" | '''Listed equities''' |
||
| style="text-align:right" | 10 |
| style="text-align:right" | 10 |
||
| style="text-align:right" | 2% |
| style="text-align:right" | 2% |
||
|- |
|- |
||
| style="text-align:left" | '''Private equity and hedge funds |
| style="text-align:left" | '''Private equity and hedge funds''' |
||
| style="text-align:right" | 23 |
| style="text-align:right" | 23 |
||
| style="text-align:right" | 5% |
| style="text-align:right" | 5% |
||
| Line 1,140: | Line 1,184: | ||
| style="text-align:right" | 0% |
| style="text-align:right" | 0% |
||
|- |
|- |
||
| style="text-align:left" | '''Total Insurance Invested |
| style="text-align:left" | '''Total Insurance Invested Assets''' |
||
| style="text-align:right" | |
| style="text-align:right" | 450 |
||
| style="text-align:right" | |
| style="text-align:right" | 100% |
||
|} |
|} |
||
</div> |
</div> |
||
=== Structured and private credit assets === |
|||
* '''Other fixed income''' includes Asset Backed Securities (EUR 25bn), Residential Loans (EUR 16bn), Commercial & Agricultural Loans (EUR 7bn), and Agency Pools (EUR 8bn) <sup>p. 33</sup>. |
|||
* '''Listed equities''' includes hedges; listed equities excluding hedges stood at EUR 14bn <sup>p. 33</sup>. |
|||
* '''Private equity and hedge funds''' includes Private Equity (EUR 17bn), Hedge Funds (EUR 5bn), and Non-listed Equities (EUR 1bn) <sup>p. 33</sup>. |
|||
* '''Total structured and private credit assets''' stood at EUR 69bn, representing 15% of the total General Account portfolio, with 54% participating <sup>p. 34</sup>. |
|||
=== Structured and private credit assets === |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Structured and |
|+ Structured and private credit assets breakdown FY25 <sup>p. 34</sup> |
||
! style="text-align:left" | Invested assets (100%) |
! style="text-align:left" | Invested assets (100%) in EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | % of total G/A¹ portfolio |
! class="col-s" style="text-align:right" | % of total G/A¹ portfolio |
||
| Line 1,183: | Line 1,225: | ||
| style="text-align:right" | 10 |
| style="text-align:right" | 10 |
||
| style="text-align:right" | 2% |
| style="text-align:right" | 2% |
||
| style="text-align:right" | - Strong diversification with EUR 8m average ticket - Investments through SMAs with strict underwriting guidelines |
| style="text-align:right" | - Strong diversification with EUR 8m average ticket - Investments through SMAs with strict underwriting guidelines: senior secured, covenants, restrictions on asset sales and sector allocation |
||
|- |
|- |
||
| style="text-align:left" | Other |
| style="text-align:left" | Other |
||
| Line 1,197: | Line 1,239: | ||
</div> |
</div> |
||
* '''General Account''' (G/A) |
* '''General Account''' (G/A) represents the investment portfolio <sup>p. 34</sup>. |
||
=== Investment portfolio | Fixed income reinvestment === |
=== Investment portfolio | Fixed income reinvestment === |
||
| Line 1,203: | Line 1,245: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ FY25 Fixed |
|+ FY25 Fixed Income Reinvestment asset mix <sup>p. 35</sup> |
||
! style="text-align:left" | Asset mix |
! style="text-align:left" | Asset mix |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share |
||
| Line 1,223: | Line 1,265: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ FY25 Fixed |
|+ FY25 Fixed Income Reinvestment Yield <sup>p. 35</sup> |
||
! style="text-align:left" | Fixed |
! style="text-align:left" | Fixed Income Type |
||
! class="col-s" style="text-align:right" | Yield |
! class="col-s" style="text-align:right" | Yield |
||
|- |
|- |
||
| Line 1,237: | Line 1,279: | ||
|} |
|} |
||
</div> |
</div> |
||
* Fixed income reinvestment totaled EUR 57bn in FY25 |
|||
* Fixed income reinvestment totaled EUR 57bn in FY25 <sup>p. 35</sup> |
|||
* Government bonds & related: average rating: AA |
|||
* Reinvestment yield achieved at 3.9% on EUR 57bn fixed income <sup>p. 35</sup> |
|||
* Investment grade credit: average rating: A |
|||
** Average duration of 9 years <sup>p. 35</sup> |
|||
* Reinvestment yield achieved at 3.9% on EUR 57bn invested |
|||
** Private & Structured Credit reinvestment of EUR 19.7bn at 4.7% yield, including CLOs, ABS, Infra & CRE debt, Fund financing, and Private HY <sup>p. 35</sup> |
|||
* Average duration of 9 years |
|||
** Strategic shift characterized by a gradual transition from alternative total return assets to Private & Structured credit <sup>p. 35</sup> |
|||
* Includes EUR 19.7bn of Private & Structured Credit invested at 4.7% (comprising CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) |
|||
* Asset allocation reflects a gradual shift from alternative total return assets to Private & Structured credit |
|||
=== Table of contents === |
=== Table of contents === |
||
* '''Debt and Invested Assets''' on page 31 <sup>p. 36</sup> |
|||
* '''Additional P&C disclosures''' on page 36 <sup>p. 36</sup> |
|||
* '''Additional IFRS17 disclosures''' on page 41 <sup>p. 36</sup> |
|||
* '''Sustainability''' on page 44 <sup>p. 36</sup> |
|||
=== AXA XL Insurance | Large Commercial & Specialty business === |
=== AXA XL Insurance | Large Commercial & Specialty business === |
||
| Line 1,251: | Line 1,297: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ FY25 GWP |
|+ FY25 GWP by line of business <sup>p. 37</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Line of business |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share |
||
|- |
|- |
||
| Line 1,272: | Line 1,318: | ||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ FY25 GWP by geography <sup>p. 37</sup> |
|+ FY25 GWP by geography <sup>p. 37</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Geography |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share |
||
|- |
|- |
||
| Line 1,286: | Line 1,332: | ||
</div> |
</div> |
||
<div style="overflow-x:auto"> |
|||
* '''Business diversification''' is well balanced across lines of business and geographies <sup>p. 37</sup> |
|||
{| class="wikitable" |
|||
* '''Market leadership''' positions AXA XL in the top 3 globally for <sup>p. 37</sup>: |
|||
|+ Profitability vs Ex-price growth (%) <sup>p. 37</sup> |
|||
! style="text-align:left" | Line of business |
|||
! class="col-m" style="text-align:right" | Profitability |
|||
! class="col-m" style="text-align:right" | Ex-price growth |
|||
|- |
|||
| style="text-align:left" | Property |
|||
| class="col-m" style="text-align:right" | high |
|||
| class="col-m" style="text-align:right" | high |
|||
|- |
|||
| style="text-align:left" | Specialty |
|||
| class="col-m" style="text-align:right" | medium-high |
|||
| class="col-m" style="text-align:right" | medium-high |
|||
|- |
|||
| style="text-align:left" | Casualty |
|||
| class="col-m" style="text-align:right" | medium |
|||
| class="col-m" style="text-align:right" | medium |
|||
|- |
|||
| style="text-align:left" | Professional lines |
|||
| class="col-m" style="text-align:right" | lower |
|||
| class="col-m" style="text-align:right" | lower |
|||
|} |
|||
</div> |
|||
* Business diversification is well balanced across lines of business and geographies <sup>p. 37</sup> |
|||
* Market leadership positions AXA XL in the top 3 globally for <sup>p. 37</sup>: |
|||
** Multinational Programs <sup>p. 37</sup> |
** Multinational Programs <sup>p. 37</sup> |
||
** Marine <sup>p. 37</sup> |
** Marine <sup>p. 37</sup> |
||
** Fine Art & Specie <sup>p. 37</sup> |
** Fine Art & Specie <sup>p. 37</sup> |
||
* |
* Cycle management is utilized to deliver consistent profitability <sup>p. 37</sup> |
||
* '''Property''': high profitability, high ex-price growth <sup>p. 37</sup> |
|||
* '''Specialty''': medium-high profitability, medium-high ex-price growth <sup>p. 37</sup> |
|||
* '''Casualty''': medium profitability, medium ex-price growth <sup>p. 37</sup> |
|||
* '''Professional lines''': lower profitability, lower ex-price growth <sup>p. 37</sup> |
|||
*** '''Professional lines''': lower profitability, lower ex-price growth <sup>p. 37</sup> |
|||
=== P&C | Focus on reserves === |
=== P&C | Focus on reserves === |
||
| Line 1,302: | Line 1,372: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Claims and |
|+ Claims and technical reserves ratios <sup>p. 38</sup> |
||
! style="text-align:left" | % |
! style="text-align:left" | % |
||
! class="col-s" style="text-align:right" | FY18 |
! class="col-s" style="text-align:right" | FY18 |
||
| Line 1,354: | Line 1,424: | ||
|} |
|} |
||
</div> |
</div> |
||
* Technical reserves definition includes net undiscounted claims reserves and unearned premium reserves <sup>p. 38</sup>. |
|||
* ¹ Includes net undiscounted claims reserves and unearned premium reserves <sup>p. 38</sup>. |
|||
=== P&C | 2026 Simplified Group Nat Cat reinsurance program 1 === |
=== P&C | 2026 Simplified Group Nat Cat reinsurance program 1 === |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable fintable" |
||
|+ Insurance segment occurrence protection |
|+ Insurance segment occurrence protection <sup>p. 39</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR |
||
! class="col-s" style="text-align:right" | Capacity |
|||
! class="col-s" style="text-align:right" | Retention |
! class="col-s" style="text-align:right" | Retention |
||
! class="col-m" style="text-align:right" | Capacity |
|||
|- |
|- |
||
| style="text-align:left" | EU Windstorm |
| style="text-align:left" | EU Windstorm |
||
| |
| style="text-align:right" | 600m |
||
| |
| style="text-align:right" | 4.0bn |
||
|- |
|- |
||
| style="text-align:left" | Europe Flood |
| style="text-align:left" | Europe Flood |
||
| |
| style="text-align:right" | 450m |
||
| |
| style="text-align:right" | 2.1bn |
||
|- |
|- |
||
| style="text-align:left" | Europe Earthquake |
| style="text-align:left" | Europe Earthquake |
||
| |
| style="text-align:right" | 400m |
||
| |
| style="text-align:right" | 2.1bn |
||
|- |
|- |
||
| style="text-align:left" | NA Hurricane |
| style="text-align:left" | NA Hurricane |
||
| |
| style="text-align:right" | 600m |
||
| |
| style="text-align:right" | 1.2bn |
||
|- |
|- |
||
| style="text-align:left" | NA Earthquake |
| style="text-align:left" | NA Earthquake |
||
| |
| style="text-align:right" | 600m |
||
| |
| style="text-align:right" | 1.2bn |
||
|- |
|- |
||
| style="text-align:left" | Per other perils |
| style="text-align:left" | Per other perils |
||
| |
| style="text-align:right" | 400m |
||
| |
| style="text-align:right" | Varies by peril type |
||
|} |
|} |
||
</div> |
</div> |
||
* Retention levels remained stable in 2026 compared to 2025 <sup>p. 39</sup>. |
|||
* (diagram) '''Reinsurance segment''' (illustrative): |
|||
* '''Retention levels''' remained stable in 2026 compared to 2025 <sup>p. 39</sup>. |
|||
* |
* Covered via '''Alternative Capital & Cat Bonds''' <sup>p. 39</sup> |
||
=== P&C | AXA Group earnings deviation with different levels of Nat Cat cost 1 in 2026 === |
=== P&C | AXA Group earnings deviation with different levels of Nat Cat cost 1 in 2026 === |
||
| Line 1,399: | Line 1,468: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 |
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 <sup>p. 40</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Return period / probability percentile |
||
! class="col-s" style="text-align:right" | EUR billion |
! class="col-s" style="text-align:right" | EUR billion |
||
|- |
|- |
||
| Line 1,431: | Line 1,500: | ||
! style="text-align:left" | Year |
! style="text-align:left" | Year |
||
! class="col-s" style="text-align:right" | EUR billion |
! class="col-s" style="text-align:right" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Estimated impact on GEP |
||
|- |
|- |
||
| style="text-align:left" | 2025 |
| style="text-align:left" | 2025 |
||
| Line 1,442: | Line 1,511: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''More severe years''' result in a negative deviation in ca. 40% of cases <sup>p. 40</sup>. |
|||
* ''' |
* '''Less severe years''' result in a positive deviation in ca. 60% of cases <sup>p. 40</sup>. |
||
* Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). <sup>p. 40</sup> |
|||
** '''More severe years''' result in a negative deviation in ca. 40% of cases <sup>p. 40</sup>. |
|||
** '''Less severe years''' result in a positive deviation in ca. 60% of cases <sup>p. 40</sup>. |
|||
* '''Natural catastrophe cost''' is defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance <sup>p. 40</sup>. |
|||
* '''Deviation comparison''' is made against a normalized level, which represents costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance) <sup>p. 40</sup>. |
|||
=== Table of contents === |
=== Table of contents === |
||
| Line 1,453: | Line 1,519: | ||
* '''Debt and Invested Assets''' <sup>p. 31</sup> |
* '''Debt and Invested Assets''' <sup>p. 31</sup> |
||
* '''Additional P&C disclosures''' <sup>p. 36</sup> |
* '''Additional P&C disclosures''' <sup>p. 36</sup> |
||
* '''Additional IFRS17 disclosures''' |
* '''Additional IFRS17 disclosures''' <sup>p. 41</sup> |
||
* '''Sustainability''' <sup>p. 44</sup> |
* '''Sustainability''' <sup>p. 44</sup> |
||
| Line 1,460: | Line 1,526: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ P&C |
|+ P&C margin analysis and underlying earnings FY25 <sup>p. 42</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|||
| style="text-align:left" | '''Current Accident Year Undiscounted Technical Margin''' |
|||
| style="text-align:right" | 2,778 |
|||
| style="text-align:right" | +707 |
|||
|- |
|||
| style="text-align:left" | '''Current Accident Year Discounting''' |
|||
| style="text-align:right" | 2,009 |
|||
| style="text-align:right" | +115 |
|||
|- |
|||
| style="text-align:left" | '''Prior Years' Reserve Development (PYD)''' |
|||
| style="text-align:right" | 622 |
|||
| style="text-align:right" | -341 |
|||
|- |
|||
| style="text-align:left" | '''Investment Income''' |
|||
| style="text-align:right" | 3,988 |
|||
| style="text-align:right" | +435 |
|||
|- |
|||
| style="text-align:left" | '''Insurance Finance Expenses''' |
|||
| style="text-align:right" | -1,358 |
|||
| style="text-align:right" | -235 |
|||
|- |
|- |
||
| style="text-align:left" | '''Underlying Earnings before tax''' |
| style="text-align:left" | '''Underlying Earnings before tax''' |
||
| Line 1,478: | Line 1,564: | ||
|- |
|- |
||
| style="text-align:left" | '''Underlying Earnings''' |
| style="text-align:left" | '''Underlying Earnings''' |
||
| style="text-align:right" | |
| style="text-align:right" | 5,872 |
||
| style="text-align:right" | |
| style="text-align:right" | +501 |
||
|- |
|||
| style="text-align:left" | ''Growth vs. FY24 (at constant FX)'' |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | ''+9%'' |
|||
|} |
|} |
||
</div> |
</div> |
||
* '''Gross earned premiums''' EUR 57,656m (+6%) <sup>p. 42</sup> |
|||
Caption: Technical result components (pre-tax, changes versus FY24 at |
|||
* '''Undiscounted |
* '''Undiscounted combined ratio''' 95.2% (-1.0pt); of which Nat Cats was 3.4% (-0.4pt) <sup>p. 42</sup> |
||
* ''' |
* '''Discounting ratio''' -3.5% (+0.0pt in Combined Ratio points) <sup>p. 42</sup> |
||
* ''' |
* '''Net claims reserves''' for current accident year at EUR 19.0bn; duration of 4.0 years; discount rate of 2.8% <sup>p. 42</sup> |
||
* ''' |
* '''PYD ratio''' -1.1% (+0.7pt) <sup>p. 42</sup> |
||
* ''' |
* '''Average assets''' for FY25 at EUR 115bn; asset book yield at 3.5%; reinvestment yield on fixed income assets at 4.3% <sup>p. 42</sup> |
||
* ''' |
* '''Reserves at locked-in rate''' for FY24 at EUR 71bn; liability book yield at 1.9% <sup>p. 42</sup> |
||
* ''' |
* '''Underlying earnings growth''' +9% vs. FY24 at constant FX <sup>p. 42</sup> |
||
* '''Discount rate sensitivity''': FY25 sensitivity to current accident year discount rate changes (parallel shift of the full-year average yield curve): |
|||
* '''Reserve development''' (prior years' PYD) of EUR 622m (-EUR 341m) with a PYD ratio of -1.1% (+0.7pt) <sup>p. 42</sup> |
|||
* |
** +25bps: +EUR 0.2bn <sup>p. 42</sup> |
||
** -25bps: -EUR 0.2bn <sup>p. 42</sup> |
|||
* '''Average assets''' (FY25) at EUR 115bn with an asset book yield of 3.5% and reinvestment yield on fixed income assets of 4.3% <sup>p. 42</sup> |
|||
* '''Insurance finance expenses''' |
* '''Insurance finance expenses''': 2026e pre-tax expected at ~EUR -1.4bn <sup>p. 42</sup> |
||
* |
** Sensitivity of 2026e expenses to changes in 2025 current AY discount: +25bps ~EUR -50m; -25bps ~EUR +50m <sup>p. 42</sup> |
||
* '''Rate increase''' of +25bps: +EUR 0.2bn <sup>p. 42</sup> |
|||
* '''Rate decrease''' of -25bps: -EUR 0.2bn <sup>p. 42</sup> |
|||
* '''Future finance expenses''' projected for 2026e (pre-tax) at ~ -EUR 1.4bn <sup>p. 42</sup>: |
|||
* '''Sensitivity to discount changes''' (+25bps in 2025 current AY discount): ~ -EUR 50m <sup>p. 42</sup> |
|||
* '''Sensitivity to discount changes''' (-25bps in 2025 current AY discount): ~ +EUR 50m <sup>p. 42</sup> |
|||
=== L&H | Margin analysis === |
=== L&H | Margin analysis === |
||
* '''L&H |
* '''L&H margin analysis''' includes scope impact <sup>p. 43</sup>. |
||
* '''Short-term |
* '''Short-term technical margin''' +EUR 60m to EUR 479m, including the recapture of Laya <sup>p. 43</sup>. |
||
* '''Gross earned premiums''' +10% to EUR 17,416m <sup>p. 43</sup>. |
|||
* '''All year combined ratio''' 97.2%, improved 0.1pts <sup>p. 43</sup>. |
|||
* '''Long-term technical margin''' +EUR 156m to EUR 2,804m <sup>p. 43</sup>. |
|||
** '''CSM release''' +EUR 215m to EUR 2,954m <sup>p. 43</sup>. |
|||
** '''Technical experience''' decreased EUR 58m to EUR -150m <sup>p. 43</sup>. |
|||
* '''Investment income''' (non-VFA only) decreased EUR 1m to EUR 2,484m <sup>p. 43</sup>. |
|||
** '''Average assets''' (FY25) at EUR 98bn with an asset book yield of 2.5% and FY25 reinvestment yield on fixed income assets of 3.8% <sup>p. 43</sup>. |
|||
* '''Insurance finance expenses''' (non-VFA only) increased EUR 9m to EUR -1,538m <sup>p. 43</sup>. |
|||
** '''Reserves at locked-in rate''' (FY24) at EUR 62bn with a liability book yield of 2.5% <sup>p. 43</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Technical |
|+ Technical and financial results in Euro million, pre-tax <sup>p. 43</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Technical and Financial Results |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
| Line 1,521: | Line 1,607: | ||
| style="text-align:right" | 479 |
| style="text-align:right" | 479 |
||
| style="text-align:right" | +60 |
| style="text-align:right" | +60 |
||
|- |
|||
| style="text-align:left" | Gross Earned Premiums |
|||
| style="text-align:right" | 17,416 |
|||
| style="text-align:right" | +10% |
|||
|- |
|||
| style="text-align:left" | All Year Combined Ratio |
|||
| style="text-align:right" | 97.2% |
|||
| style="text-align:right" | -0.1pts |
|||
|- |
|- |
||
| style="text-align:left" | Long-term Technical Margin |
| style="text-align:left" | Long-term Technical Margin |
||
| style="text-align:right" | 2,804 |
| style="text-align:right" | 2,804 |
||
| style="text-align:right" | +156 |
| style="text-align:right" | +156 |
||
|- |
|||
| style="text-align:left" | CSM release |
|||
| style="text-align:right" | 2,954 |
|||
| style="text-align:right" | +215 |
|||
|- |
|||
| style="text-align:left" | Technical experience |
|||
| style="text-align:right" | -150 |
|||
| style="text-align:right" | -58 |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Financial Result (In Euro million, pre-tax) <sup>p. 43</sup> |
|||
! style="text-align:left" | Metric |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | Investment Income (non-VFA only) |
| style="text-align:left" | Investment Income (non-VFA only) |
||
| Line 1,560: | Line 1,621: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''Investment Income details (non-VFA only)''': |
|||
** '''FY25 Average Assets''': EUR 98bn <sup>p. 43</sup> |
|||
** '''Asset book yield''': 2.5% <sup>p. 43</sup> |
|||
** '''FY25 Reinvestment yield¹''': 3.8% <sup>p. 43</sup> |
|||
* '''Insurance Finance Expenses details (non-VFA only)''': |
|||
** '''FY24 Reserves at locked-in rate''': EUR 62bn <sup>p. 43</sup> |
|||
** '''Liability book yield''': 2.5% <sup>p. 43</sup> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying |
|+ Underlying earnings bridge in Euro million <sup>p. 43</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Underlying Earnings |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
| Line 1,594: | Line 1,647: | ||
</div> |
</div> |
||
* '''Underlying |
* '''Underlying earnings growth''' +7% versus FY24 at constant FX <sup>p. 43</sup>. |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Life & Health FY25 CSM |
|+ Life & Health FY25 CSM key sensitivities in Euro billion <sup>p. 43</sup> |
||
! style="text-align:left" | Sensitivity |
! style="text-align:left" | Sensitivity |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Impact |
||
|- |
|- |
||
| style="text-align:left" | Baseline |
| style="text-align:left" | Baseline |
||
| Line 1,630: | Line 1,683: | ||
|} |
|} |
||
</div> |
</div> |
||
* ¹ Reinvestment yield on fixed income assets <sup>p. 43</sup>. |
|||
=== Table of contents === |
=== Table of contents === |
||
* '''Debt and Invested Assets''' <sup>p. 31</sup> |
|||
* '''Additional P&C disclosures''' <sup>p. 36</sup> |
|||
* '''Additional IFRS17 disclosures''' <sup>p. 41</sup> |
|||
* '''Sustainability''' <sup>p. 44</sup> |
|||
=== Expanding AXA's role in society: AXA for Progress Index 1 === |
=== Expanding AXA's role in society: AXA for Progress Index 1 === |
||
<div style="overflow-x:auto"> |
|||
* '''As a Global Investor''': |
|||
{| class="wikitable" |
|||
** '''Climate transition financing''': Target of EUR 5bn per year in climate transition financing <sup>p. 45</sup>; 2025 Result achieved EUR 6.4bn <sup>p. 45</sup>. |
|||
|+ ESG targets and achievements <sup>p. 45</sup> |
|||
** '''Community resilience financing''': Target of >EUR 500m per year <sup>p. 45</sup>; 2025 Result achieved EUR 1.4bn <sup>p. 45</sup>. |
|||
! style="text-align:left" | Category |
|||
* '''As a Global Insurer''': |
|||
! class="col-m" style="text-align:right" | Target |
|||
** '''Transition underwriting''': Target of EUR 6bn in P&C GWP to support transition underwriting (cumulative 2024-2026) <sup>p. 45</sup>; 2025 Result achieved EUR 4.6bn <sup>p. 45</sup>. |
|||
! class="col-m" style="text-align:right" | Achieved in 2025 |
|||
** '''Climate adaptation solutions''': Target of >20,000 climate adaptation solutions & services (cumulative 2024-2026, target revised in 2025) <sup>p. 45</sup>; 2025 Result achieved 19,698 cumulative 2024-2025 <sup>p. 45</sup>. |
|||
|- |
|||
** '''Inclusive insurance''': Target of >20m inclusive insurance customers by 2026 <sup>p. 45</sup>; 2025 Result achieved 20.6m <sup>p. 45</sup>. |
|||
| style="text-align:left" | Climate transition financing |
|||
* '''As a Company''': |
|||
| class="col-m" style="text-align:right" | EUR 5bn per year |
|||
** '''Climate adaptation training''': Target of >80,000 AXA Group employees trained on climate adaptation by 2026 <sup>p. 45</sup>; 2025 Result achieved 46,420 <sup>p. 45</sup>. |
|||
| class="col-m" style="text-align:right" | EUR 6.4bn |
|||
** '''Carbon emissions reduction''': Target to contribute to Net-Zero with -50% by 2030 in absolute carbon emissions and offset of residual emissions <sup>p. 45</sup>; 2025 Result achieved -64% reduction against 2019 <sup>p. 45</sup>. |
|||
|- |
|||
** '''Employee volunteering''': Target of 50% of AXA Group employees engaged in volunteering activities by 2026 <sup>p. 45</sup>; 2025 Result achieved 56% <sup>p. 45</sup>. |
|||
| style="text-align:left" | Community resilience financing |
|||
| class="col-m" style="text-align:right" | >EUR 500m per year |
|||
| class="col-m" style="text-align:right" | EUR 1.4bn |
|||
|- |
|||
| style="text-align:left" | Transition underwriting (cumulative 2024-2026) |
|||
| class="col-m" style="text-align:right" | EUR 6bn in P&C GWP |
|||
| class="col-m" style="text-align:right" | EUR 4.6bn |
|||
|- |
|||
| style="text-align:left" | Climate adaptation solutions (cumulative 2024-2026) |
|||
| class="col-m" style="text-align:right" | >20,000 |
|||
| class="col-m" style="text-align:right" | 19,698 (cumulative 2024-2025) |
|||
|- |
|||
| style="text-align:left" | Inclusive insurance customers |
|||
| class="col-m" style="text-align:right" | >20m by 2026 |
|||
| class="col-m" style="text-align:right" | 20.6m |
|||
|- |
|||
| style="text-align:left" | Climate adaptation training |
|||
| class="col-m" style="text-align:right" | >80,000 employees by 2026 |
|||
| class="col-m" style="text-align:right" | 46,420 |
|||
|- |
|||
| style="text-align:left" | Carbon emissions reduction |
|||
| class="col-m" style="text-align:right" | -50% by 2030 |
|||
| class="col-m" style="text-align:right" | -64% against 2019 |
|||
|- |
|||
| style="text-align:left" | Employee volunteering |
|||
| class="col-m" style="text-align:right" | 50% of employees by 2026 |
|||
| class="col-m" style="text-align:right" | 56% |
|||
|} |
|||
</div> |
|||
=== Sustainability Performance & Ratings === |
=== Sustainability Performance & Ratings === |
||
| Line 1,653: | Line 1,738: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable" |
||
|+ ESG ratings |
|+ ESG ratings <sup>p. 46</sup> |
||
! style="text-align:left" | Rating |
! style="text-align:left" | Rating Agency |
||
! class="col- |
! class="col-s" style="text-align:right" | Score |
||
|- |
|- |
||
| style="text-align:left" | S&P Global |
| style="text-align:left" | S&P Global percentile |
||
| class="col- |
| class="col-s" style="text-align:right" | 97th |
||
|- |
|- |
||
| style="text-align:left" | MSCI |
| style="text-align:left" | MSCI |
||
| class="col- |
| class="col-s" style="text-align:right" | AAA |
||
|- |
|- |
||
| style="text-align:left" | CDP |
| style="text-align:left" | CDP |
||
| class="col- |
| class="col-s" style="text-align:right" | B |
||
|- |
|- |
||
| style="text-align:left" | Morningstar Sustainalytics |
| style="text-align:left" | Morningstar Sustainalytics |
||
| class="col- |
| class="col-s" style="text-align:right" | 17.0 - Low risk |
||
|- |
|- |
||
| style="text-align:left" | FTSE Russell |
| style="text-align:left" | FTSE Russell |
||
| class="col- |
| class="col-s" style="text-align:right" | 4.3/5 |
||
|} |
|} |
||
</div> |
</div> |
||
* '''S&P Global''' 2025 percentile: 97th in Dow Jones Best-in-Class Europe & World indices <sup>p. 46</sup>; the CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (specifically AXA Restricted Shares), with results as of February 6th, 2026 <sup>p. 46</sup> |
|||
* The Corporate Sustainability Assessment (CSA) ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (specifically AXA Restricted Shares), with results as of February 6th, 2026 <sup>p. 46</sup>. |
|||
* '''FTSE Russell''' 2025 score: 4.3/5 in FTSE4Good Index Series <sup>p. 46</sup> |
|||
* '''Morningstar Sustainalytics rating''': 2025 ESG Risk Rating of 17.0 – Low risk <sup>p. 46</sup> |
|||
* '''FTSE Russell score''': 4.3/5 in FTSE4Good Index Series <sup>p. 46</sup> |
|||
=== Scope === |
=== Scope === |
||
* '''France''' includes insurance activities, banking activities, and holding <sup>p. 47</sup>. |
* '''France''' scope includes insurance activities, banking activities, and holding <sup>p. 47</sup>. |
||
* '''Europe''' includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities), and AXA Life Europe (insurance activities) <sup>p. 47</sup>. |
* '''Europe''' scope includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities), and AXA Life Europe (insurance activities) <sup>p. 47</sup>. |
||
* '''AXA XL''' includes insurance and reinsurance activities and holding <sup>p. 47</sup>. |
* '''AXA XL''' scope includes insurance and reinsurance activities and holding <sup>p. 47</sup>. |
||
* '''Asia, Africa & EME-LATAM''' includes: |
* '''Asia, Africa & EME-LATAM''' scope includes: |
||
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated; |
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated; China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S, and India (Life activities disposed on March 11, 2024 and holding) businesses which are consolidated under the equity method and contribute only to NBV, PVEP, the underlying earnings, and net income <sup>p. 47</sup>. |
||
** '''Africa''': Morocco (insurance activities and holding), Nigeria (insurance activities and holding), and Egypt (insurance activities and holding) which are fully consolidated <sup>p. 47</sup>. |
** '''Africa''': Morocco (insurance activities and holding), Nigeria (insurance activities and holding), and Egypt (insurance activities and holding) which are fully consolidated <sup>p. 47</sup>. |
||
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) which are fully consolidated |
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) which are fully consolidated, as well as Russia (Reso) (insurance activities) which is consolidated under the equity method and contributes only to net income <sup>p. 47</sup>. |
||
** '''AXA Mediterranean Holdings''' <sup>p. 47</sup>. |
** '''AXA Mediterranean Holdings''' <sup>p. 47</sup>. |
||
* '''Transversal & Other''' includes AXA Assistance, AXA Liabilities Managers, AXA, and other Central Holdings <sup>p. 47</sup>. |
* '''Transversal & Other''' scope includes AXA Assistance, AXA Liabilities Managers, AXA, and other Central Holdings <sup>p. 47</sup>. |
||
* '''AXA Investment Managers''' (until July 1, 2025) includes AXA Investment Managers, Select (previously referred to as Architas), and Capza which are fully consolidated, and Asian joint ventures which are consolidated under the equity method <sup>p. 47</sup>. |
* '''AXA Investment Managers''' (until July 1, 2025) scope includes AXA Investment Managers, Select (previously referred to as Architas), and Capza which are fully consolidated, and Asian joint ventures which are consolidated under the equity method <sup>p. 47</sup>. |
||
* '''Accounting standards''' |
* '''Accounting standards''' comparative figures going back to 2023 are under IFRS17/9 standards (effective January 1, 2023); figures prior to 2023 have not been restated and are presented under IFRS4 <sup>p. 47</sup>. |
||
=== Glossary === |
=== Glossary === |
||
| Line 1,703: | Line 1,790: | ||
* '''Operating variance''': the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes. Operating variance is net of reinsurance <sup>p. 48</sup> |
* '''Operating variance''': the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes. Operating variance is net of reinsurance <sup>p. 48</sup> |
||
* '''Present value of expected premiums (PVEP)''': the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share <sup>p. 48</sup> |
* '''Present value of expected premiums (PVEP)''': the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share <sup>p. 48</sup> |
||
* '''Technical experience''': consists of the impacts on the underlying earnings |
* '''Technical experience''': consists of the impacts on the underlying earnings of (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses <sup>p. 48</sup> |
||
* '''Underlying return on in-force''': represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance <sup>p. 48</sup> |
* '''Underlying return on in-force''': represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance <sup>p. 48</sup> |
||
=== February 26, 2026 Thank you Full Year 2025 earnings === |
=== February 26, 2026 Thank you Full Year 2025 earnings === |
||
* |
* '''Closing slide''' for the AXA Full Year 2025 Earnings presentation, dated February 26, 2026 <sup>p. 49</sup>. |
||
== Abbreviations == |
== Abbreviations == |
||
* '''AA''': |
* '''AA''': Senior bond rating |
||
* '''AAA''': |
* '''AAA''': Senior bond rating |
||
* '''ABS''': Asset-Backed Securities |
* '''ABS''': Asset-Backed Securities |
||
* '''AEP''': Aggregate Exceedance Probability |
* '''AEP''': Aggregate Exceedance Probability |
||
* '''AI''': Artificial Intelligence |
* '''AI''': Artificial Intelligence |
||
* '''AMF''': Autorité des marchés financiers |
|||
* '''APAC''': Asia-Pacific |
* '''APAC''': Asia-Pacific |
||
* '''AXA IM''': AXA Investment Managers |
* '''AXA IM''': AXA Investment Managers |
||
* '''AXA XL''': AXA |
* '''AXA XL''': AXA Corporate Solutions and XL Catlin |
||
* '''AY''': Accident Year |
* '''AY''': Accident Year |
||
* '''BBA''': |
* '''BBA''': Benefit-Bearing Account |
||
* '''CDP''': Carbon Disclosure Project |
* '''CDP''': Carbon Disclosure Project |
||
* '''CLO''': Collateralized Loan Obligation |
* '''CLO''': Collateralized Loan Obligation |
||
| Line 1,728: | Line 1,816: | ||
* '''CSM''': Contractual Service Margin |
* '''CSM''': Contractual Service Margin |
||
* '''CY''': Calendar Year |
* '''CY''': Calendar Year |
||
* '''DPS''': Dividend Per Share |
|||
* '''EME''': Emerging Markets |
* '''EME''': Emerging Markets |
||
* '''EOF''': Eligible Own Funds |
* '''EOF''': Eligible Own Funds |
||
* '''EPS''': Earnings Per Share |
* '''EPS''': Earnings Per Share |
||
* '''ESG''': Environmental, Social, and Governance |
* '''ESG''': Environmental, Social, and Governance |
||
* '''ESMA''': European Securities and Markets Authority |
|||
* '''EU''': European Union |
* '''EU''': European Union |
||
* '''EUR''': Euro |
|||
* '''FX''': Foreign Exchange |
* '''FX''': Foreign Exchange |
||
* '''GAAP''': Generally Accepted Accounting Principles |
* '''GAAP''': Generally Accepted Accounting Principles |
||
* '''GBP''': Great British Pound |
|||
* '''GEP''': Gross Earned Premium |
* '''GEP''': Gross Earned Premium |
||
* '''GF EUR''': Grandfathered Euro |
|||
* '''GF GBP''': Grandfathered British Pound |
|||
* '''GWP''': Gross Written Premiums |
* '''GWP''': Gross Written Premiums |
||
* '''HKD''': Hong Kong Dollar |
* '''HKD''': Hong Kong Dollar |
||
| Line 1,755: | Line 1,845: | ||
* '''NPS''': Net Promoter Score |
* '''NPS''': Net Promoter Score |
||
* '''OCI''': Other Comprehensive Income |
* '''OCI''': Other Comprehensive Income |
||
* '''PAA''': |
* '''PAA''': Participating Account Agreement |
||
* '''PE''': Private Equity |
* '''PE''': Private Equity |
||
* '''PVEP''': Present Value of Expected Profits |
* '''PVEP''': Present Value of Expected Profits |
||
* '''PYD''': Prior |
* '''PYD''': Prior Years' Reserve Development |
||
* '''RCG''': Reinsurance |
* '''RCG''': Reinsurance Capital Generation |
||
* '''ROE''': Return on Equity |
* '''ROE''': Return on Equity |
||
* '''SCR''': Solvency Capital Requirement |
* '''SCR''': Solvency Capital Requirement |
||
| Line 1,768: | Line 1,858: | ||
* '''UK''': United Kingdom |
* '''UK''': United Kingdom |
||
* '''US''': United States |
* '''US''': United States |
||
* '''USD''': United States Dollar |
|||
* '''VAT''': Value Added Tax |
* '''VAT''': Value Added Tax |
||
* '''VFA''': Variable Fee Approach |
* '''VFA''': Variable Fee Approach |
||
Revision as of 18:51, 23 June 2026
| Document info | |
|---|---|
| Organization | AXA |
| Year | 2025 |
| Period | FY |
| Period label | FY25 |
| Document type | Analyst presentation |
| Publication date | 2026-02-26 |
| Language | English |
| Pages | 49 |
| Source | Original URL |
This article summarizes AXA's full-year 2025 earnings presentation, published on 26 February 2026.
Front matter
Full Year 2025 earnings presentation
- AXA Full Year 2025 earnings presentation delivered on February 26, 2026 p. 1
Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures
- Forward-looking statements include predictions, trends, plans, expectations, or objectives based on Management's current views and subject to change p. 2.
- Expected UEPS growth for 2026 is provided as one-off guidance in the context of the final year of the Group's current strategic plan p. 2.
- Risk factors and uncertainties that may affect AXA's business are described in Part 5 "Risk Factors and Risk Management" of AXA's 2024 Universal Registration Document p. 2.
- Alternative performance measures (APMs) used include "underlying earnings", UEPS ("underlying earnings per share"), "underlying return on equity", "combined ratio", and "debt gearing" p. 2.
- APMs are defined under ESMA guidelines and the AMF's 2015 position statement, with reconciliations provided in AXA's 2025 Activity Report p. 2.
- Financial statements status: AXA's consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of audit procedures p. 2.
Table of contents
- FY25 Highlights presented by Thomas Buberl, Group CEO p. 3, 4
- FY25 Business Performance presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology p. 3, 9
- FY25 Financial Performance presented by Alban de Mailly Nesle, Group CFO p. 3, 13
FY25 Highlights
- Section divider slide for FY25 Highlights, presented by Thomas Buberl, Group CEO p. 4.
Full Year 2025 | Excellent performance
| Metric | Value |
|---|---|
| Revenues growth vs. FY24 | +6% |
| Underlying EPS growth vs. FY24 | +8% |
| Return on equity | 16% |
| Solvency II ratio | 224% |
| DPS growth | +8% |
| Annual share buyback | EUR 1.25bn |
| Underlying EPS outlook for 2026 | Upper end of 6%-8% target range |
- Dividend proposal based on Board of Directors' recommendation on February 25, 2026, subject to Shareholders' Annual General Meeting approval on April 30, 2026
- Share buyback approved by the Board of Directors on February 25, 2026, expected to commence as soon as reasonably practicable, subject to market conditions
Executing the plan on growth, margin and efficiency
| EUR billion unless otherwise mentioned | FY24 | FY25 | Change (constant FX) | Change (excluding AXA IM) |
|---|---|---|---|---|
| Underlying earnings | 8.1 | 8.4 | +6% | +9% |
- High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%)
- Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency
- Scaling the business: Continued investments in growth and technology
- Consistent earnings growth while enhancing reserve prudence
Diversified franchise, well positioned in an attractive industry
| Segment | Share |
|---|---|
| Life | 33% |
| Health | 17% |
| Large & Specialty | 17% |
| Retail | 17% |
| SME & Mid-market | 16% |
- Secular trends fuel demand across businesses, driven by protection gaps and emerging corporate risks, as well as demographics driving demand for private retirement and healthcare
- Our right to win is supported by four strategic pillars:
- Leading brand & high customer NPS
- Strong and diversified distribution
- Technical expertise to price & underwrite risks
- Scale offering cost advantage
Laying the foundation for the next plan
- Strategic pillars established to lay the foundation for the next plan:
- Clear tech and AI roadmap p. 8
- Driving efficiency across operations p. 8
- Enhancing capital allocation discipline p. 8
- Building resilience across the business p. 8
- Earnings growth outlook supported by strong foundations, providing confidence in sustaining earnings growth p. 8
Business Performance
FY25 business performance
- Section 2: FY25 Business Performance presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology p. 9.
Strong delivery across our businesses
- Premium growth basis: change for gross written premiums is at constant scope and FX p. 10.
- Earnings growth basis: change for underlying earnings is at constant FX p. 10.
- Total GWP definition: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers p. 10.
| Region (share of total GWP¹) | Gross written premiums | Underlying earnings |
|---|---|---|
| France (27% of total GWP¹) | +6% to EUR 31bn | +7% to EUR 2.2bn |
| Europe (38% of total GWP¹) | +6% to EUR 43bn | +9% to EUR 3.5bn |
| AXA XL (17% of total GWP¹) | +4% to EUR 19bn | +9% to EUR 1.9bn |
| Asia, Africa & EME-LATAM (18% of total GWP¹) | +13% to EUR 20bn | +6% to EUR 1.5bn |
P&C | Strong margins, confidence in sustaining growth
- Gross written premiums (GWP) reached EUR 58bn p. 11.
- (donut) GWP mix: Retail, AXA XL (Large & Specialty), SME & Mid-market — shares not labeled p. 11.
- AXA XL GWP includes AXA XL Re premiums of EUR 2.6bn p. 11.
- Underlying earnings +9% at constant FX to EUR 5.9bn p. 11.
- Retail and SME & Mid-market strategic outlook:
- 2025: Growing volumes while expanding margins p. 11.
- Beyond 2025: Investing to improve customer retention and expanding distribution footprint p. 11.
- AXA XL (Large & Specialty) strategic outlook:
- 2025: Profitable growth with stable margins p. 11.
- Beyond 2025: Capitalizing on attractive growth opportunities and continued cycle management p. 11.
- Earnings drivers supporting performance:
- Continued progress on efficiency p. 11.
- Higher investment income p. 11.
- Data & AI to further enhance customer experience and technical excellence p. 11.
L&H | Good momentum, well positioned to capture growth opportunities
- Gross written premiums (GWP) reached EUR 57bn p. 12.
- (donut) GWP mix: Short-term and Long-term segments — shares not labeled p. 12.
- Underlying earnings +7% LFL to EUR 3.5bn (change FY25 vs. FY24 at constant FX) p. 12.
- Long-term business strategic priorities:
- 2025: Accelerating net flows in Savings at attractive margins p. 12.
- Beyond 2025: Capturing savings & retirement opportunity, sourcing best asset management products for our customers p. 12.
- Short-term business strategic priorities:
- 2025: Growing technical results while absorbing Mexico VAT impact p. 12.
- Beyond 2025: Capitalizing on demand for health & protection while further improving our margins p. 12.
- Strategic levers for growth and efficiency:
- Focus on cost reduction p. 12.
- Increasing penetration of Protection riders in Savings offerings p. 12.
- Leveraging AI to reduce claims leakage & improve customer outcomes in Health p. 12.
Financial Performance
FY25 financial performance
- Section 3: FY25 Financial Performance presented by Alban de Mailly Nesle, Group CFO p. 13
P&C | Continued disciplined growth
| EUR billion unless otherwise mentioned | FY24 | FY25 | Change | o/w pricing | o/w volume |
|---|---|---|---|---|---|
| Commercial lines | — | 35.8 | +4% | +2% | +2% |
| AXA XL Reinsurance | — | 2.6 | +8% | +0.3% | +7% |
| Retail lines | — | 19.7 | +7% | +5% | +2% |
| Total | 56.5 | 58.0 | +5% | — | — |
- Continued pricing momentum and volume growth in Mid-market and SME
- Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance
- Growth supported by alternative capital
- Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25)
P&C | Delivering further margin expansion while enhancing reserve prudence
| Combined ratio | FY24 | FY25 |
|---|---|---|
| Undiscounted CY loss ratio (ex Nat Cat) | 67.4% | 67.0% |
| Expense ratio | 25.0% | 24.8% |
| Nat Cat | 3.8% | 3.4% |
| Prior year reserve development | -1.6% | -1.1% |
| Discount | -3.6% | -3.5% |
| Total combined ratio | 91.0% | 90.6% |
- Undiscounted CY loss ratio (ex Nat Cat) improved from:
- Margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment
- Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management
- Expense ratio improved reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology
- Nat Cat charges below normalized load
- Prior year reserve development shows lower reliance
- Reserve prudence enhanced by taking advantage of a good year
P&C | Earnings growth from higher underwriting and financial result
| EUR million | Underlying earnings |
|---|---|
| FY24 | 5,510 |
| Volume growth | +292 |
| Margin improvement | +189 |
| Investment income | +435 |
| Insurance finance expenses | -235 |
| Tax | -169 |
| Affiliates, FX & other | -150 |
| FY25 | 5,872 |
- Underlying earnings grew +9% at constant FX to EUR 5,872m.
- Underwriting result improved from strong volume growth and improved all-year combined ratio while enhancing reserve prudence.
- Investment income increased reflecting higher volumes and better reinvestment yields on fixed income assets.
- Insurance finance expenses impacted by higher unwind of discount of claims reserves, in line with guidance.
- Forex impact was unfavorable, notably due to USD depreciation vs. EUR.
| EUR billion unless otherwise mentioned | FY24 | FY25 | LFL Change |
|---|---|---|---|
| Life GWP | 34.5 | 37.5 | +9% |
| Protection | — | 17.3 | +11% |
| Unit-linked | — | 9.3 | +13% |
| Capital light G/A | — | 9.0 | +7% |
| Traditional G/A | — | 1.9 | -7% |
| Health GWP | 17.5 | 19.0 | +5% |
| Individual | — | 10.5 | +6% |
| Group | — | 8.5 | +4% |
| Employee Benefits GWP | — | 12.9 | +4% |
| EUR billion | FY24 | FY25 |
|---|---|---|
| Total | 1.5 | 5.4 |
| Protection | — | 4.9 |
| Health | — | 2.7 |
| Unit-Linked | — | 1.5 |
| Capital light G/A | — | 1.2 |
| Traditional G/A | — | -5.0 |
Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting
| EUR billion unless otherwise mentioned | FY24 | FY25 | LFL Change |
|---|---|---|---|
| Total PVEP | 50.9 | 49.4 | -2% |
| Protection & Health | — | 31.4 | -4% |
| Unit-Linked | — | 8.5 | +18% |
| Capital-light G/A | — | 7.8 | -10% |
| Traditional G/A | — | 1.7 | -10% |
| EUR billion | FY24 | FY25 | LFL Change |
|---|---|---|---|
| NB CSM (pre-tax) | 2.2 | 2.2 | +3% |
| NBV (post-tax) | 2.3 | 2.2 | stable |
- PVEP impacted by higher interest rates on discounting despite strong growth in Life volumes p. 18.
- NB CSM driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits p. 18.
- NBV broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France p. 18.
- NBV margin: 4.4% in FY24 → 4.5% in FY25 p. 18
Life & Health | Growth in new business driving Normalized CSM growth
| EUR billion | Value |
|---|---|
| FY24 | 33.6 |
| New business CSM | +2.2 |
| Underlying return on in-force | +1.3 |
| CSM release | -3.0 |
| Economic variance | +0.6 |
| Operating variance | -0.3 |
| Affiliates, FX & other | -1.4 |
| FY25 | 33.0 |
- Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates p. 19
- Economic variance reflecting government spreads tightening and positive equity market returns p. 19
- Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland p. 19
- FX impact mainly from JPY and HKD depreciation p. 19
- (waterfall) Contractual Service Margin rollforward (in EUR billion): FY24 EUR 33.6bn (o/w Life EUR 25.8bn, o/w Health EUR 7.7bn) → New business CSM +EUR 2.2bn → Underlying return on in-force +EUR 1.3bn → CSM release -EUR 3.0bn (Normalized CSM growth +2%) → Economic variance +EUR 0.6bn → Operating variance -EUR 0.3bn → Affiliates, FX & other -EUR 1.4bn → FY25 EUR 33.0bn (o/w Life EUR 25.4bn, o/w Health EUR 7.6bn) p. 19
Life & Health | Strong momentum in both short-term and long-term business
| EUR million | Underlying earnings |
|---|---|
| FY24 start | 3,323 |
| Short-term technical margin | +60 |
| Long-term result incl. CSM release | +156 |
| Financial result | -11 |
| Tax, FX and others | -27 |
| FY25 end | 3,501 |
- Underlying earnings +7% LFL to EUR 3,501m p. 20
- Short-term technical margin: EUR 415m in FY24 to EUR 479m in FY25 p. 20
- Long-term result incl. CSM release: EUR 2,680m in FY24 to EUR 2,804m in FY25 p. 20
- Financial result: EUR 975m in FY24 to EUR 946m in FY25 p. 20
- Tax & others: EUR -748m in FY24 to EUR -728m in FY25 p. 20
- Life underlying earnings +4% to EUR 2.7bn (prior: EUR 2.6bn) p. 20
- Health underlying earnings +17% to EUR 0.8bn (prior: EUR 0.7bn) p. 20
- Short-term margin strong on underwriting and claims initiatives; more than offset legislative change on Mexico VAT recoverability of EUR -0.1bn p. 20
- Long-term results higher from CSM release increase of +8% on reserve base growth, favorable equity markets, and better margins p. 20
Growth in net income reflecting higher earnings & the gain from the sale of AXA IM
| EUR billion unless otherwise mentioned | FY24 | FY25 | Change |
|---|---|---|---|
| Property & Casualty | 5.5 | 5.9 | +9% |
| Life & Health | 3.3 | 3.5 | +7% |
| Asset Management | 0.4 | 0.2 | -57% |
| Holdings & other | -1.2 | -1.2 | - |
| Underlying earnings | 8.1 | 8.4 | +6% |
| Non-financial flows | -0.5 | +2.1 | — |
| o/w capital gains from AXA IM disposal | - | +2.2 | — |
| Financial flows (incl. RCG) | +0.3 | -0.7 | — |
| Net income | 7.9 | 9.8 | +26% |
| EUR | Underlying earnings per share |
|---|---|
| FY24 | 3.59 |
| Earnings growth | +6% |
| Capital management | +3% |
| Forex | -2% |
| Temporary earnings dilution from AXA IM sale | -1% |
| FY25 | 3.86 |
- Underlying earnings drivers:
- Strong performance from insurance businesses p. 21
- Stable holding cost, expected to remain at current level in 2026 p. 21
- Net income drivers:
- Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM p. 21
- Lower financial flows reflecting unfavorable forex impact p. 21
- Change is at constant FX for underlying earnings and net income; change is on a reported basis for underlying earnings per share p. 21
- (bar) Underlying earnings per share (In Euro): EUR 3.59 in FY24 to EUR 3.86 in FY25 (+8%) p. 21
- (stacked bar) Shareholders' equity Group share:
- FY24: EUR 49.9bn total (comprising SHE excl. OCI EUR 58.0bn and Net OCI EUR -8.1bn) p. 22
- HY25: EUR 45.5bn total (comprising SHE excl. OCI EUR 52.7bn and Net OCI EUR -7.2bn) p. 22
- FY25: EUR 47.2bn total (comprising SHE excl. OCI EUR 54.0bn and Net OCI EUR -6.8bn) p. 22
- SHE (excl. OCI & undated subordinated debt): EUR 53.2bn in FY24 → EUR 47.0bn in HY25 → EUR 49.4bn in FY25 p. 22
- Debt gearing: 20.6% in FY24 → 23.4% in HY25 → 22.3% in FY25 p. 22
- Underlying ROE: 15.2% in FY24 → 17.5% in HY25 → 16.0% in FY25 p. 22
| EUR billion | FY24 to FY25 | HY25 to FY25 |
|---|---|---|
| Opening Shareholders' equity | 49.9 | 45.5 |
| Change in Net OCI | 1.3 | 0.4 |
| Net income for the period | 9.8 | 5.9 |
| Dividend | -4.6 | - |
| Annual share buyback | -1.2 | - |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 | -3.5 |
| Undated subordinated debt (including interest charges) | -0.3 | -1.2 |
| Forex | -3.5 | -0.1 |
| Other | -0.6 | 0.3 |
| Closing Shareholders' equity | 47.2 | 47.2 |
Higher organic cash remittance and robust cash position at Holding
- (bar) Net cash remittance trend:
- FY24: EUR 7.7bn total, comprising EUR 7.1bn ordinary remittance and EUR 0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe p. 23
- FY25: EUR 7.5bn total p. 23
- Remittance ratio remained stable at 82% in FY24 and 82% in FY25, based on ordinary cash remittance of EUR 7.1bn in FY24 and EUR 7.5bn in FY25 p. 23
| EUR billion | — |
|---|---|
| FY24 Cash position | 4.0 |
| Net cash remittance from subsidiaries | +7.5 |
| Dividend | -4.6 |
| Annual share buyback | -1.2 |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 |
| Holding costs and interest expenses | -1.3 |
| Change in net debt | +1.6 |
| M&A and other | +3.1 |
| FY25 Cash position | 5.6 |
Solvency II at 224%
| EUR billion unless otherwise mentioned | EOF | SCR | Solvency II ratio (pts) |
|---|---|---|---|
| FY24 | 55.9 | 25.9 | 216 |
| Regulatory & model changes | +0.2 | 0.0 | +0 |
| Normalized capital generation | +8.8 | +0.6 | +28 |
| Operating variance | -0.4 | 0.0 | -1 |
| Economic variance & FX | -2.1 | -1.2 | +4 |
| Dividend & annual share buyback | -6.0 | 0.0 | -24 |
| Management actions, debt & other | -0.1 | -0.2 | +2 |
| FY25 | 56.4 | 25.2 | 224 |
- Foreseeable dividends accounted for -EUR 4.8bn.
- Provision for annual share buyback for 2026 accounted for -EUR 1.25bn.
| Sensitivity | Impact (pts) |
|---|---|
| Interest rate +50bps | +2 |
| Interest rate -50bps | -1 |
| Corporate spreads +50bps | -1 |
| Euro Sovereign spreads +50bps | -7 |
| Credit migration | -4 |
| Listed Equity (excluding PE & Infra) +25% | -1 |
| Listed Equity (excluding PE & Infra) -25% | +2 |
| PE & Infra +25% | +14 |
| PE & Infra -25% | -19 |
| Inflation swap curve +50bps | -5 |
- Euro sovereign spreads sensitivity assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve, applied on sovereign and quasi-sovereign exposures.
- Credit rating migration sensitivity assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).
Solvency II -impact of the end of grandfathering period and Solvency II revision
| Event | Impact (pts) |
|---|---|
| Solvency II ratio as of December 31, 2025 | 224 |
| Grandfathering end impact on January 1, 2026 | -10 |
| Solvency II revision impact to come into effect in 1Q27 | +17 |
- EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026.
- No change is expected in organic capital generation.
- Provides additional capital flexibility.
- Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.
- Grandfathering end impact on January 1, 2026 is -10pts to 215% p. 25.
Thomas Buberl, Group CEO conclusion
- Section divider for the conclusion presentation by Thomas Buberl, Group CEO p. 26.
Conclusion
- Record results achieved at the top end of the target range while enhancing reserve prudence p. 27.
- All businesses in excellent shape, delivering strong growth and profitability p. 27.
- Diversified franchise well-positioned to capture future growth opportunities p. 27.
- Laying foundations for the next plan and confident in delivering sustainable earnings growth p. 27.
February 26, 2026 Q&A Full Year 2025 earnings
- Q&A session for the Full Year 2025 Earnings presentation held on February 26, 2026 p. 28.
AXA Investor Relations | Keep in touch
- Investor Relations contact: +33 1 40 75 48 42; investor.relations@axa.com p. 29
- Follow us: www.axa.com p. 29
| Date | Event | Location |
|---|---|---|
| March | Roadshows | Europe and US |
| May 5 | 1Q25 Activity Indicators | Paris |
| June 2 | BNP Paribas Exane CEO Conference | Paris |
| June 2-4 | Goldman Sachs European Financials Conference | Zurich |
| July 31 | HY26 Earnings Release | Paris |
| September 21 | AXA Investor Day | London |
Appendices
- Section divider for Appendices p. 30
Table of contents
- Debt and Invested Assets p. 31
- Additional P&C disclosures p. 36
- Additional IFRS17 disclosures p. 41
- Sustainability p. 44
Gross financial debt and maturity breakdown as of December 31st, 2025
| EUR billion unless otherwise mentioned | FY24 | FY25 | Jan 1st 2026 |
|---|---|---|---|
| Tier 1 | 4.8 | 4.6 | 3.2 |
| Tier 2 | 10.8 | 12.2 | 11.3 |
| Senior debt | 3.5 | 3.5 | 5.8 |
| Total | 19.2 | 20.3 | 20.3 |
| Debt gearing | 20.6% | 22.3% | — |
| EUR billion | Tier 1 | Tier 2 | Senior debt |
|---|---|---|---|
| 2028 | — | — | 0.5 |
| 2030 | — | 0.7 | 0.9 |
| 2031-2039 | — | — | 1.5 |
| ≥2040 | — | 10.8 | 0.5 |
| Undated | 4.6 | 0.7 | — |
| Grandfathered debt (contractual) | — | — | — |
| Tier 1 Undated | 1.4 | — | — |
| Tier 2 2030 | — | 0.7 | — |
| Tier 2 ≥2040 | — | 0.2 | — |
| EUR billion | Tier 1 | Tier 2 | Senior debt |
|---|---|---|---|
| 2026 | 0.1 | — | — |
| 2027 | — | 2.4 | — |
| 2028 | 0.1 | — | 0.5 |
| 2029 | — | 2.0 | — |
| 2030 | — | 0.7 | 0.9 |
| 2031-2039 | 0.4 | 6.4 | 1.5 |
| ≥2040 | — | — | 0.5 |
| Undated | 4.0 | 0.7 | — |
| Grandfathered debt (economic) | — | — | — |
| Tier 1 2026 | 0.1 | — | — |
| Tier 1 2028 | 0.1 | — | — |
| Tier 1 2031-2039 | 0.4 | — | — |
| Tier 1 Undated | 0.8 | — | — |
| Tier 2 2030 | — | 0.7 | — |
| Tier 2 ≥2040 | — | 0.2 | — |
- In January 2026, AXA called the remaining Tier 2 grandfathered GBP 139m due 2054 callable 2034 (5.625% issued January 2014) and the Tier 1 grandfathered EUR 250m perpetual callable 2010 floating (issued January 2005).
- Economic maturity accounts for the first date of step-up calls on institutionally placed subordinated debt.
- For Solvency II RT1 debt with no step-up, the undated nature of the instrument is retained for economic maturity.
General account invested assets
- Total General Account invested assets at EUR 450bn p. 33.
- Duration gap at -0.4 year p. 33.
- (donut) FY25 General Account invested assets: EUR 450bn total; mix includes Fixed income, Real estate, Infrastructure equity, Listed equities, Private equity and hedge funds, Cash, and Policy loans p. 33.
- Other fixed income includes Asset Backed Securities (EUR 25bn), Residential Loans (EUR 16bn), Commercial & Agricultural Loans (EUR 7bn), and Agency Pools (EUR 8bn) p. 33.
- Listed equities includes hedges; listed equities excluding hedges at EUR 14bn p. 33.
- Private equity and hedge funds includes Private Equity (EUR 17bn), Hedge Funds (EUR 5bn), and Non-listed Equities (EUR 1bn) p. 33.
| EUR billion unless otherwise mentioned | FY25 | % |
|---|---|---|
| Fixed income | 345 | 77% |
| o/w Government bonds | 167 | 37% |
| o/w Corporate bonds and loans | 121 | 27% |
| o/w Other fixed income | 56 | 13% |
| Real estate | 41 | 9% |
| Infrastructure equity | 10 | 2% |
| Listed equities | 10 | 2% |
| Private equity and hedge funds | 23 | 5% |
| Cash | 19 | 4% |
| Policy loans | 2 | 0% |
| Total Insurance Invested Assets | 450 | 100% |
Structured and private credit assets
- Total structured and private credit assets stood at EUR 69bn, representing 15% of the total General Account portfolio, with 54% participating p. 34.
| Invested assets (100%) in EUR billion unless otherwise mentioned | FY25 | % of total G/A¹ portfolio | Comments |
|---|---|---|---|
| Residential Mortgages | 16 | 4% | - EUR 6bn Dutch mortgages, NHG guaranteed - EUR 10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) |
| CLO & ABS | 25 | 6% | - 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) |
| Infrastructure debt | 8 | 2% | - Skewed towards resilient industries (Telecom, Utilities, Transport) |
| CRE debt | 8 | 2% | - Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV |
| Mid-Market lending | 10 | 2% | - Strong diversification with EUR 8m average ticket - Investments through SMAs with strict underwriting guidelines: senior secured, covenants, restrictions on asset sales and sector allocation |
| Other | 2 | 0% | — |
| Total Structured and Private Credit Assets | 69 | 15% | o/w 54% participating |
- General Account (G/A) represents the investment portfolio p. 34.
Investment portfolio | Fixed income reinvestment
| Asset mix | Share |
|---|---|
| Government bonds & related | 32% |
| Investment grade credit | 40% |
| ABS/CLO/IG fund financing | 21% |
| Below investment grade credit | 7% |
| Fixed Income Type | Yield |
|---|---|
| Public fixed income | 3.5% |
| Private & Structured fixed income | 4.7% |
| Total fixed income | 3.9% |
- Fixed income reinvestment totaled EUR 57bn in FY25 p. 35
- Reinvestment yield achieved at 3.9% on EUR 57bn fixed income p. 35
- Average duration of 9 years p. 35
- Private & Structured Credit reinvestment of EUR 19.7bn at 4.7% yield, including CLOs, ABS, Infra & CRE debt, Fund financing, and Private HY p. 35
- Strategic shift characterized by a gradual transition from alternative total return assets to Private & Structured credit p. 35
Table of contents
- Debt and Invested Assets on page 31 p. 36
- Additional P&C disclosures on page 36 p. 36
- Additional IFRS17 disclosures on page 41 p. 36
- Sustainability on page 44 p. 36
AXA XL Insurance | Large Commercial & Specialty business
| Line of business | Share |
|---|---|
| Casualty | 35% |
| Property | 29% |
| Specialty | 19% |
| Professional lines (including Cyber) | 17% |
| Geography | Share |
|---|---|
| Americas | 46% |
| Europe & APAC | 35% |
| UK & Lloyds | 19% |
| Line of business | Profitability | Ex-price growth |
|---|---|---|
| Property | high | high |
| Specialty | medium-high | medium-high |
| Casualty | medium | medium |
| Professional lines | lower | lower |
- Business diversification is well balanced across lines of business and geographies p. 37
- Market leadership positions AXA XL in the top 3 globally for p. 37:
- Multinational Programs p. 37
- Marine p. 37
- Fine Art & Specie p. 37
- Cycle management is utilized to deliver consistent profitability p. 37
- Property: high profitability, high ex-price growth p. 37
- Specialty: medium-high profitability, medium-high ex-price growth p. 37
- Casualty: medium profitability, medium ex-price growth p. 37
- Professional lines: lower profitability, lower ex-price growth p. 37
P&C | Focus on reserves
| % | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Claims reserves ratio (IFRS4 basis) | 179 | 185 | 193 | 188 | 189 | — | — | — |
| Claims reserves ratio (IFRS17 basis) | — | — | — | — | 198 | 195 | 180 | 175 |
| Technical reserves ratio (IFRS4 basis) | 213 | 227 | 233 | 226 | 227 | — | — | — |
| Technical reserves ratio (IFRS17 basis) | — | — | — | — | 234 | 232 | 216 | 210 |
- Technical reserves definition includes net undiscounted claims reserves and unearned premium reserves p. 38.
P&C | 2026 Simplified Group Nat Cat reinsurance program 1
| EUR | Retention | Capacity |
|---|---|---|
| EU Windstorm | 600m | 4.0bn |
| Europe Flood | 450m | 2.1bn |
| Europe Earthquake | 400m | 2.1bn |
| NA Hurricane | 600m | 1.2bn |
| NA Earthquake | 600m | 1.2bn |
| Per other perils | 400m | Varies by peril type |
- Retention levels remained stable in 2026 compared to 2025 p. 39.
- (diagram) Reinsurance segment (illustrative):
- Covered via Alternative Capital & Cat Bonds p. 39
P&C | AXA Group earnings deviation with different levels of Nat Cat cost 1 in 2026
| Return period / probability percentile | EUR billion |
|---|---|
| 1/20y (95th percentile) | -1.2 |
| 1/10y (90th percentile) | -0.8 |
| 1/5y (80th percentile) | -0.4 |
| Median (50th percentile) | +0.1 |
| 1/5y (20th percentile) | +0.5 |
| 1/10y (10th percentile) | +0.7 |
| 1/20y (5th percentile) | +0.8 |
| Year | EUR billion | Estimated impact on GEP |
|---|---|---|
| 2025 | 2.6 | ca. 4.5% |
| 2026 | 2.7 | ca. 4.5% |
- More severe years result in a negative deviation in ca. 40% of cases p. 40.
- Less severe years result in a positive deviation in ca. 60% of cases p. 40.
- Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). p. 40
Table of contents
- Debt and Invested Assets p. 31
- Additional P&C disclosures p. 36
- Additional IFRS17 disclosures p. 41
- Sustainability p. 44
P&C | Margin analysis
| EUR million | FY25 | Change |
|---|---|---|
| Current Accident Year Undiscounted Technical Margin | 2,778 | +707 |
| Current Accident Year Discounting | 2,009 | +115 |
| Prior Years' Reserve Development (PYD) | 622 | -341 |
| Investment Income | 3,988 | +435 |
| Insurance Finance Expenses | -1,358 | -235 |
| Underlying Earnings before tax | 8,040 | +681 |
| Tax | -2,060 | -169 |
| Affiliates, Minority interests & Other | -108 | -10 |
| Underlying Earnings | 5,872 | +501 |
- Gross earned premiums EUR 57,656m (+6%) p. 42
- Undiscounted combined ratio 95.2% (-1.0pt); of which Nat Cats was 3.4% (-0.4pt) p. 42
- Discounting ratio -3.5% (+0.0pt in Combined Ratio points) p. 42
- Net claims reserves for current accident year at EUR 19.0bn; duration of 4.0 years; discount rate of 2.8% p. 42
- PYD ratio -1.1% (+0.7pt) p. 42
- Average assets for FY25 at EUR 115bn; asset book yield at 3.5%; reinvestment yield on fixed income assets at 4.3% p. 42
- Reserves at locked-in rate for FY24 at EUR 71bn; liability book yield at 1.9% p. 42
- Underlying earnings growth +9% vs. FY24 at constant FX p. 42
- Discount rate sensitivity: FY25 sensitivity to current accident year discount rate changes (parallel shift of the full-year average yield curve):
- +25bps: +EUR 0.2bn p. 42
- -25bps: -EUR 0.2bn p. 42
- Insurance finance expenses: 2026e pre-tax expected at ~EUR -1.4bn p. 42
- Sensitivity of 2026e expenses to changes in 2025 current AY discount: +25bps ~EUR -50m; -25bps ~EUR +50m p. 42
L&H | Margin analysis
- L&H margin analysis includes scope impact p. 43.
- Short-term technical margin +EUR 60m to EUR 479m, including the recapture of Laya p. 43.
- Gross earned premiums +10% to EUR 17,416m p. 43.
- All year combined ratio 97.2%, improved 0.1pts p. 43.
- Long-term technical margin +EUR 156m to EUR 2,804m p. 43.
- CSM release +EUR 215m to EUR 2,954m p. 43.
- Technical experience decreased EUR 58m to EUR -150m p. 43.
- Investment income (non-VFA only) decreased EUR 1m to EUR 2,484m p. 43.
- Average assets (FY25) at EUR 98bn with an asset book yield of 2.5% and FY25 reinvestment yield on fixed income assets of 3.8% p. 43.
- Insurance finance expenses (non-VFA only) increased EUR 9m to EUR -1,538m p. 43.
- Reserves at locked-in rate (FY24) at EUR 62bn with a liability book yield of 2.5% p. 43.
| Technical and Financial Results | FY25 | Change |
|---|---|---|
| Short-term Technical Margin | 479 | +60 |
| Long-term Technical Margin | 2,804 | +156 |
| Investment Income (non-VFA only) | 2,484 | -1 |
| Insurance Finance Expenses (non-VFA only) | -1,538 | -9 |
| Underlying Earnings | FY25 | Change |
|---|---|---|
| Underlying Earnings before tax | 4,229 | +205 |
| Tax | -800 | 65 |
| Affiliates, Minority interests & Other | 72 | -51 |
| Underlying Earnings | 3,501 | +219 |
- Underlying earnings growth +7% versus FY24 at constant FX p. 43.
| Sensitivity | Impact |
|---|---|
| Baseline | 33.3 |
| Interest rates +50bps | -0.8 |
| Interest rates -50bps | 0.6 |
| Sovereign spreads +50bps | -1.9 |
| Sovereign spreads -50bps | 1.9 |
| Corporate spread +50bps | -0.8 |
| Corporate spread -50bps | 0.7 |
| Equities +25% | 1.8 |
| Equities -25% | -2.2 |
Table of contents
- Debt and Invested Assets p. 31
- Additional P&C disclosures p. 36
- Additional IFRS17 disclosures p. 41
- Sustainability p. 44
Expanding AXA's role in society: AXA for Progress Index 1
| Category | Target | Achieved in 2025 |
|---|---|---|
| Climate transition financing | EUR 5bn per year | EUR 6.4bn |
| Community resilience financing | >EUR 500m per year | EUR 1.4bn |
| Transition underwriting (cumulative 2024-2026) | EUR 6bn in P&C GWP | EUR 4.6bn |
| Climate adaptation solutions (cumulative 2024-2026) | >20,000 | 19,698 (cumulative 2024-2025) |
| Inclusive insurance customers | >20m by 2026 | 20.6m |
| Climate adaptation training | >80,000 employees by 2026 | 46,420 |
| Carbon emissions reduction | -50% by 2030 | -64% against 2019 |
| Employee volunteering | 50% of employees by 2026 | 56% |
Sustainability Performance & Ratings
| Rating Agency | Score |
|---|---|
| S&P Global percentile | 97th |
| MSCI | AAA |
| CDP | B |
| Morningstar Sustainalytics | 17.0 - Low risk |
| FTSE Russell | 4.3/5 |
- The Corporate Sustainability Assessment (CSA) ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (specifically AXA Restricted Shares), with results as of February 6th, 2026 p. 46.
- Morningstar Sustainalytics rating: 2025 ESG Risk Rating of 17.0 – Low risk p. 46
- FTSE Russell score: 4.3/5 in FTSE4Good Index Series p. 46
Scope
- France scope includes insurance activities, banking activities, and holding p. 47.
- Europe scope includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities), and AXA Life Europe (insurance activities) p. 47.
- AXA XL scope includes insurance and reinsurance activities and holding p. 47.
- Asia, Africa & EME-LATAM scope includes:
- Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated; China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S, and India (Life activities disposed on March 11, 2024 and holding) businesses which are consolidated under the equity method and contribute only to NBV, PVEP, the underlying earnings, and net income p. 47.
- Africa: Morocco (insurance activities and holding), Nigeria (insurance activities and holding), and Egypt (insurance activities and holding) which are fully consolidated p. 47.
- EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) which are fully consolidated, as well as Russia (Reso) (insurance activities) which is consolidated under the equity method and contributes only to net income p. 47.
- AXA Mediterranean Holdings p. 47.
- Transversal & Other scope includes AXA Assistance, AXA Liabilities Managers, AXA, and other Central Holdings p. 47.
- AXA Investment Managers (until July 1, 2025) scope includes AXA Investment Managers, Select (previously referred to as Architas), and Capza which are fully consolidated, and Asian joint ventures which are consolidated under the equity method p. 47.
- Accounting standards comparative figures going back to 2023 are under IFRS17/9 standards (effective January 1, 2023); figures prior to 2023 have not been restated and are presented under IFRS4 p. 47.
Glossary
- Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0% p. 48
- Contractual Service Margin (CSM): a component of the carrying amount of asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders p. 48
- CSM release: a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period p. 48
- Economic variance: corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force p. 48
- Financial result: consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder's equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow p. 48
- Gross Written Premiums and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) p. 48
- New Business Value (NBV): the value of newly issued contracts during the current year. It consists of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests p. 48
- New Business Contractual Service Margin (NB CSM): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided p. 48
- New Business Value margin (NBV margin): ratio of (i) NBV, representing the value of newly issued contracts during the current year, to (ii) PVEP p. 48
- Operating variance: the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes. Operating variance is net of reinsurance p. 48
- Present value of expected premiums (PVEP): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share p. 48
- Technical experience: consists of the impacts on the underlying earnings of (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses p. 48
- Underlying return on in-force: represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance p. 48
February 26, 2026 Thank you Full Year 2025 earnings
- Closing slide for the AXA Full Year 2025 Earnings presentation, dated February 26, 2026 p. 49.
Abbreviations
- AA: Senior bond rating
- AAA: Senior bond rating
- ABS: Asset-Backed Securities
- AEP: Aggregate Exceedance Probability
- AI: Artificial Intelligence
- AMF: Autorité des marchés financiers
- APAC: Asia-Pacific
- AXA IM: AXA Investment Managers
- AXA XL: AXA Corporate Solutions and XL Catlin
- AY: Accident Year
- BBA: Benefit-Bearing Account
- CDP: Carbon Disclosure Project
- CLO: Collateralized Loan Obligation
- CRE: Commercial Real Estate
- CSA: Corporate Sustainability Assessment
- CSM: Contractual Service Margin
- CY: Calendar Year
- DPS: Dividend Per Share
- EME: Emerging Markets
- EOF: Eligible Own Funds
- EPS: Earnings Per Share
- ESG: Environmental, Social, and Governance
- ESMA: European Securities and Markets Authority
- EU: European Union
- EUR: Euro
- FX: Foreign Exchange
- GAAP: Generally Accepted Accounting Principles
- GBP: Great British Pound
- GEP: Gross Earned Premium
- GWP: Gross Written Premiums
- HKD: Hong Kong Dollar
- HY: High Yield
- IFE: Insurance Finance Expenses
- IFRS: International Financial Reporting Standards
- IG: Investment Grade
- JPY: Japanese Yen
- LATAM: Latin America
- LFL: Like-for-Like
- LTV: Loan-to-Value
- MSCI: Morgan Stanley Capital International
- NA: North America
- NB CSM: New Business Contractual Service Margin
- NBV: New Business Value
- NHG: Nationale Hypotheek Garantie
- NPS: Net Promoter Score
- OCI: Other Comprehensive Income
- PAA: Participating Account Agreement
- PE: Private Equity
- PVEP: Present Value of Expected Profits
- PYD: Prior Years' Reserve Development
- RCG: Reinsurance Capital Generation
- ROE: Return on Equity
- SCR: Solvency Capital Requirement
- SHE: Shareholders' Equity
- SME: Small and Medium-sized Enterprises
- TVOG: Time Value of Options and Guarantees
- UEPS: Underlying Earnings Per Share
- UK: United Kingdom
- US: United States
- VAT: Value Added Tax
- VFA: Variable Fee Approach